[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 432
1. Nordenvall C, Nyrén O, Ye W: Elevated anal squamous cell carcinoma risk associated with benign inflammatory anal lesions. Gut; 2006 May;55(5):703-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated anal squamous cell carcinoma risk associated with benign inflammatory anal lesions.
  • BACKGROUND: The association between benign anal lesions and anal cancer is still unclear.
  • Few data from large cohort studies are available.
  • Multiple record linkages identified all incident anal (squamous cell carcinoma only) and colorectal cancers through to 2002.
  • Among inflammatory lesion and haemorrhoid patients, a significantly increased risk of colorectal cancer was observed only in the first year after hospitalisation.
  • CONCLUSIONS: Inflammatory benign anal lesions are associated with a significantly increased long term risk of anal cancer.
  • [MeSH-major] Anus Neoplasms / complications. Carcinoma, Squamous Cell / complications

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Radiol Oncol. 1984;23(5):305-13 [6095600.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] N Engl J Med. 1990 Nov 1;323(18):1228-33 [2215606.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Prog Growth Factor Res. 1992;4(2):121-37 [1338573.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):300-2 [8022440.001]
  • [Cites] N Engl J Med. 1995 Jan 19;332(3):190-1 [7695719.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241 [7715068.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Gut. 1997 Oct;41(4):522-5 [9391253.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1534-8 [9836490.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):1047-52 [10201481.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):473-83 [11506482.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G626-34 [11518674.001]
  • [Cites] J Physiol Paris. 2001 Jan-Dec;95(1-6):417-22 [11595469.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G515-20 [15010360.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • (PMID = 16299038.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1856114
  •  go-up   go-down


2. Sheng SL, Huang G, Yu B, Qin WX: Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem; 2009 Sep;55(9):1656-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By use of this method, we investigated the serum concentrations of DKK1 in 592 patients with malignancies, 72 patients with benign lung disease, and 120 healthy controls.
  • RESULTS: Serum DKK1 concentrations were significantly higher in patients with lung cancer than in patients with other malignant tumors or benign lung diseases and healthy controls.
  • Serum concentrations of DKK1 were decreased significantly in groups of patients with gastric cancer, colorectal cancer, ovarian cancer, and cervical adenocarcinoma compared with healthy controls.
  • DKK1 concentrations increased with stage, tumor class, and presence of lymph node and distant metastases, regardless of histology and patient age and sex.
  • Increasing concentrations of DKK1were significantly associated with tumor progression and decreased survival in patients with lung cancer. .
  • [MeSH-major] Biomarkers, Tumor / blood. Fluoroimmunoassay / methods. Intercellular Signaling Peptides and Proteins / blood. Lung Neoplasms / blood
  • [MeSH-minor] Aged. Calibration. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19628661.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


3. Shantha Kumara HM, Cabot JC, Hoffman A, Luchtefeld M, Kalady MF, Hyman N, Feingold D, Baxter R, Whelan RL: Minimally invasive colon resection is associated with a transient increase in plasma sVEGFR1 levels and a decrease in sVEGFR2 levels during the early postoperative period. Surg Endosc; 2009 Apr;23(4):694-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Plasma vascular endothelial growth factor (VEGF) levels are elevated for 2-4 weeks after minimally invasive colorectal resection (MICR).
  • VEGF induces wound and tumor angiogenesis by binding to endothelial cell (EC)-bound VEGF-receptor 1 (VEGFR1) and VEGFR2.
  • The importance of the MICR-related VEGF changes depends on the effect of surgical procedures on sVEGFR1 and sVEGFR2; this study assessed levels of these proteins after MICR for benign indications.
  • [MeSH-minor] Biomarkers / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / diagnosis. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Follow-Up Studies. Humans. Intraoperative Period. Middle Aged. Postoperative Period. Prognosis. Prospective Studies

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):44-50 [7615975.001]
  • [Cites] Clin Chem Lab Med. 1998 Jun;36(6):379-83 [9711425.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):295-301 [18782657.001]
  • [Cites] J Vasc Surg. 1998 Sep;28(3):535-40 [9737465.001]
  • [Cites] Am J Cardiol. 1999 Feb 1;83(3):337-9 [10072219.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):405-10 [17214745.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):490-8 [10667605.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):14-8 [11857378.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Sci STKE. 2001 Dec 11;2001(112):re21 [11741095.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):608-13 [16891801.001]
  • [Cites] Crit Care Med. 2008 Apr;36(4):1284-9 [18379256.001]
  • [Cites] Clin Chem. 2001 Apr;47(4):617-23 [11274009.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3824-30 [10339489.001]
  • [Cites] Shock. 2008 Apr;29(4):452-7 [18598002.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):792-8 [17060773.001]
  • [Cites] Eur Surg Res. 2003 Nov-Dec;35(6):492-6 [14593233.001]
  • [Cites] Circ Res. 2001 Feb 2;88(2):167-74 [11157668.001]
  • [Cites] Clin Sci (Lond). 1997 May;92(5):453-4 [9176017.001]
  • [Cites] Surg Endosc. 2009 Feb;23(2):409-15 [18813991.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):1931-4 [11929804.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):331-5 [12653578.001]
  • [Cites] Eur Respir J. 2001 Jul;18(1):100-6 [11510779.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Cancer. 2004 May 1;100(9):1884-91 [15112269.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4332-9 [14555503.001]
  • [Cites] Clin Exp Immunol. 2000 Jan;119(1):182-8 [10606981.001]
  • [Cites] J Exp Med. 1992 Nov 1;176(5):1375-9 [1402682.001]
  • (PMID = 19184203.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


Advertisement
4. Fujii H, Jiang W, Matsumoto T, Miyai K, Sashara K, Ohtsuji N, Hino O: Birt-Hogg-Dubé gene mutations in human endometrial carcinomas with microsatellite instability. J Pathol; 2006 Jul;209(3):328-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Birt-Hogg-Dubé (BHD) syndrome is a rare form of autosomal dominantly inherited genodermatosis characterized by benign hamartomatous skin lesions named fibrofolliculomas, and an increased risk for developing pulmonary cyst/pneumothorax and various forms of renal cell carcinoma.
  • This mutational hot spot is also reported to be a target of mutation in microsatellite instability (MSI) sporadic colorectal cancer.
  • Of these, one showed additional mutation in exon 4, possibly satisfying the two-hit hypothesis of tumour suppressor genes.
  • When multiple foci were microdissected and individually screened for mutation, BHD mutations were shown to have been acquired during tumour progression, after mutation of the BAX gene, in three of five cases.
  • [MeSH-major] Endometrial Neoplasms / genetics. Microsatellite Repeats / genetics. Mutation. Neoplastic Syndromes, Hereditary / genetics. Proteins / genetics. Proto-Oncogene Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Aged, 80 and over. Base Sequence. Carrier Proteins / genetics. DNA Methylation. DNA-Binding Proteins / genetics. Disease Progression. Female. Humans. Microdissection / methods. Middle Aged. Molecular Sequence Data. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. bcl-2-Associated X Protein / genetics

  • Genetic Alliance. consumer health - Birt-Hogg-Dube Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16691634.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / FLCN protein, human; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


5. Betambeau N, Simson JN: Staged anterior resection and TEM to preserve rectal function in synchronous malignant and benign rectal lesions. Colorectal Dis; 2007 Jun;9(5):469-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staged anterior resection and TEM to preserve rectal function in synchronous malignant and benign rectal lesions.
  • BACKGROUND: Traditionally patients with a high rectosigmoid carcinoma and a synchronous large distal rectal adenoma would be treated by low anterior resection with associated loss of rectal function.
  • Preoperative and postoperative rectal function was assessed using the St. Mark's incontinence score.
  • [MeSH-major] Adenoma / surgery. Carcinoma / surgery. Endoscopy / methods. Neoplasms, Multiple Primary / surgery. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504346.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Rao M, Sagar P, Duff S, Hulme-Moir M, Brayshaw I: Laparoscopic excision of a retrorectal schwannoma. Tech Coloproctol; 2010 Dec;14(4):353-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retrorectal tumors are uncommon and are usually managed by open surgical excision.
  • Recent advances in laparoscopic techniques have led to the use of laparoscopy for a variety of problems in colorectal surgery, including the excision of retrorectal tumours.
  • This case report, which describes the laparoscopic excision of a benign schwannoma arising from the second sacral nerve root, highlights the benefits of accurate preoperative diagnosis with MR imaging and the advantages of a laparoscopic approach while pointing out principles that should be adhered to when using this approach.
  • The tumour was successfully resected without neural compromise and with a prompt and full postoperative recovery.
  • [MeSH-major] Laparoscopy. Neurilemmoma / surgery. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1663-5 [15937628.001]
  • [Cites] Br J Surg. 2008 Feb;95(2):214-21 [17933000.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):644-52 [2996861.001]
  • (PMID = 20454822.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Endreseth BH, Wibe A, Svinsås M, Mårvik R, Myrvold HE: Postoperative morbidity and recurrence after local excision of rectal adenomas and rectal cancer by transanal endoscopic microsurgery. Colorectal Dis; 2005 Mar;7(2):133-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight patients with benign pre-operative histopathological examination had cancer.
  • CONCLUSION: TEM is a safe technique well tolerated also by high-risk patients, and should be the preferred method in patients with benign tumours in the middle and upper part of the rectum, and in selected cases of early rectal cancer.
  • Benign pre-operative histology does not preclude malignancy and some patients may need further treatment for unexpected malignancy.
  • [MeSH-major] Adenoma / surgery. Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonoscopy. Endosonography. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15720349.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Petrova TV, Nykänen A, Norrmén C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe F, von Melchner H, Gradwohl G, Vanharanta S, Aaltonen LA, Saharinen J, Gentile M, Clarke A, Taipale J, Oliver G, Alitalo K: Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell; 2008 May;13(5):407-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype.
  • The Drosophila transcription factor Prospero functions as a tumor suppressor, and it has been suggested that the human counterpart of Prospero, PROX1, acts similarly in human cancers.
  • However, we show here that PROX1 promotes dysplasia in colonic adenomas and colorectal cancer progression.
  • PROX1 expression marks the transition from benign colon adenoma to carcinoma in situ, and its loss inhibits growth of human colorectal tumor xenografts and intestinal adenomas in Apc(min/+) mice, while its transgenic overexpression promotes colorectal tumorigenesis.
  • Furthermore, in intestinal tumors PROX1 is a direct and dose-dependent target of the beta-catenin/TCF signaling pathway, responsible for the neoplastic transformation.
  • Our data underscore the complexity of cancer pathogenesis and implicate PROX1 in malignant tumor progression through the regulation of cell polarity and adhesion.
  • [MeSH-major] Adenoma / genetics. Colonic Neoplasms / genetics. Homeodomain Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Carcinoma in Situ / genetics. Cell Line, Tumor. Colorectal Neoplasms / genetics. Disease Progression. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Phenotype. beta Catenin / physiology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455124.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United Kingdom / Worldwide Cancer Research / / 09-0791; United Kingdom / Medical Research Council / / G0301154
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Tumor Suppressor Proteins; 0 / beta Catenin; 0 / prospero-related homeobox 1 protein
  •  go-up   go-down


9. Shah AJ, Phull J, Finch-Jones MD: Clinical risk score can be used to select patients for staging laparoscopy and laparoscopic ultrasound for colorectal liver metastases. World J Surg; 2010 Sep;34(9):2141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical risk score can be used to select patients for staging laparoscopy and laparoscopic ultrasound for colorectal liver metastases.
  • BACKGROUND: Despite advanced staging investigations, some patients with potentially resectable colorectal liver metastases (CLM) are unresectable at laparotomy.
  • All patients whose tumors were deemed resectable proceeded to Lap + LUS.
  • In 15 of 74 patients, LUS prevented an unnecessary laparotomy by predicting the benign nature of lesions or demonstrating unresectability.
  • [MeSH-major] Colorectal Neoplasms / pathology. Laparoscopy. Liver Neoplasms / diagnostic imaging. Patient Selection

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):183-9 [12620915.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):293-9 [11224615.001]
  • [Cites] Ann Surg. 2007 Aug;246(2):295-300 [17667509.001]
  • [Cites] Eur J Surg Oncol. 2004 Oct;30(8):834-41 [15336728.001]
  • [Cites] Ann Oncol. 2005 May;16(5):762-6 [15817597.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):31-7 [10400033.001]
  • [Cites] Br J Surg. 2006 Aug;93(8):1001-6 [16739103.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):388-95 [11786565.001]
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] Br J Surg. 1986 Sep;73(9):732-5 [3756437.001]
  • [Cites] Am J Clin Oncol. 2005 Dec;28(6):565-9 [16317265.001]
  • [Cites] Ann Surg. 1989 Aug;210(2):127-38 [2667471.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Arch Surg. 2003 Jul;138(7):770-2 [12860759.001]
  • [Cites] World J Surg. 1982 Jan;6(1):32-45 [7090394.001]
  • [Cites] Br J Surg. 2003 Sep;90(9):1131-6 [12945082.001]
  • [Cites] Br J Surg. 2007 Jul;94(7):855-9 [17380479.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):457-64 [16555242.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] ANZ J Surg. 2004 Dec;74(12 ):1056-9 [15574147.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12 ):1766-72 [15550581.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50 [15319715.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):77-81 [17030548.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1177-89 [10914907.001]
  • [Cites] Radiology. 2005 Oct;237(1):170-80 [16126930.001]
  • [Cites] Ann Surg. 1994 Dec;220(6):711-9 [7986136.001]
  • [Cites] J Am Coll Surg. 1999 Jan;188(1):33-42 [9915240.001]
  • [Cites] Int J Colorectal Dis. 1991 May;6(2):111-4 [1875119.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):158-69 [10100781.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):487-99 [10749608.001]
  • [Cites] Cancer. 2001 Mar 15;91(6):1121-8 [11267957.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):347-53 [11352309.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Surgery. 1991 Jul;110(1):13-29 [1866690.001]
  • (PMID = 20532771.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Li W, Fan W: Using 18F-FDG positron emission tomography/computed tomography to judge benign or malignant colorectal hypermetabolic lesions. Chin J Cancer; 2010 Mar;29(3):306-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using 18F-FDG positron emission tomography/computed tomography to judge benign or malignant colorectal hypermetabolic lesions.
  • The thickness of the colorectal wall is unfixed because it changes following wall contractions.
  • These anatomic and physiologic factors can bring a few difficulties in correctly judging colorectal information on 18F-FDG positron emission tomography/computed tomography (PET/CT) scans.
  • This study was to discuss the imaging characteristics of colorectal hypermetabolic lesions in 18F-FDG PET/CT and their value to clinical diagnosis.
  • METHODS: According the metabolic characteristics and the shape of the lesion, 118 colorectal hypermetabolic lesions of 74 patients were detected by 18F-FDG PET/CT and separated to 6 groups (localized/CT+, localized/CT-, segmented/CT+, segmented/CT-, diffuse/CT+, diffuse/CT-).
  • CONCLUSIONS: On 18F-FDG PET/CT, colorectal hypermetabolic lesions in the diffuse/CT- or segmented/CT- groups were highly likely to be nonmalignant and those in the segmented/CT+ group were highly likely to be malignant.
  • To correctly diagnose colorectal hypermetabolic lesions, it is necessary to analyze the PET of the metabolism and the CT of the anatomy together.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Fluorodeoxyglucose F18. Multimodal Imaging / methods. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adenomatous Polyps / diagnosis. Adenomatous Polyps / radiography. Adenomatous Polyps / radionuclide imaging. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / radiography. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193115.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


11. Lee JH, Ross WA, Davila R, Chang G, Lin E, Dekovich A, Davila M: Self-expandable metal stents (SEMS) can serve as a bridge to surgery or as a definitive therapy in patients with an advanced stage of cancer: clinical experience of a tertiary cancer center. Dig Dis Sci; 2010 Dec;55(12):3530-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Self-expandable metal stents (SEMS) can be used to relieve benign and malignant colorectal obstruction.
  • AIMS: The aim of this study was to determine the outcomes of SEMS for malignant colorectal obstruction.
  • Cancer types included: 28 colorectal, and 18 metastatic cancers.
  • CONCLUSIONS: Placement of SEMS for the treatment of colorectal obstruction is feasible and safe.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colon, Sigmoid / pathology. Colorectal Neoplasms / complications. Colorectal Neoplasms / pathology. Constriction, Pathologic. Female. Fluoroscopy. Foreign-Body Migration / epidemiology. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prosthesis Design. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1992 Jun;174(6):513-8 [1595029.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):444-50 [14994110.001]
  • [Cites] Surg Endosc. 2002 Oct;16(10):1483-7 [11988801.001]
  • [Cites] Br J Surg. 1994 Sep;81(9):1270-6 [7953385.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):914-20 [17140898.001]
  • [Cites] Gastrointest Endosc. 2007 Nov;66(5):920-7 [17904133.001]
  • [Cites] Surg Endosc. 2006 Jun;20(6):909-14 [16738981.001]
  • [Cites] Surg Endosc. 2010 Feb;24(2):400-6 [19551432.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):265-8 [15015606.001]
  • [Cites] Gastrointest Endosc. 2007 Nov;66(5):931-6 [17767930.001]
  • [Cites] Gastrointest Endosc. 2004 Dec;60(6):865-74 [15604999.001]
  • [Cites] Dis Colon Rectum. 2004 Sep;47(9):1455-61 [15486741.001]
  • [Cites] Endoscopy. 2008 Mar;40(3):184-91 [18322873.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):2051-7 [15447772.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):76-81 [15213621.001]
  • (PMID = 20721627.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Belinsky GS, Claffey KP, Nambiar PR, Guda K, Rosenberg DW: Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line. Mol Carcinog; 2005 Jun;43(2):65-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The organo-specific carcinogen, azoxymethane (AOM), produces colon tumors in mice that share many pathological features with sporadic human colorectal cancer (CRC).
  • To assess the role of the microenvironment in preventing the invasive phenotype, multiple benign in situ adenocarcinomas were harvested from AOM-treated mice and cultured in vitro.
  • However, tumor cell growth was extremely limiting under standard culturing conditions.
  • Thus, we injected tumor cells directly into nude mice and performed two serial transplants, and successfully explanted a rapidly growing epithelial tumor cell line (AJ02nm(0)).
  • When injected subcutaneously (sc) into nude mice, AJ02nm(0) cells formed well-differentiated adenocarcinomas with minimal tumor invasive capacity.
  • AJ02nm-VEGF cells produced rapidly growing tumors in nude mice that exhibited extensive pseudo-epithelial ductal architecture and supporting vasculature, but without increased invasive potential compared to controls.
  • [MeSH-major] Colonic Neoplasms / blood supply. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / physiology
  • [MeSH-minor] Animals. Antigens, CD31 / analysis. Apoptosis. Cell Division. Cell Line, Tumor. Colorectal Neoplasms / blood supply. Colorectal Neoplasms / pathology. Karyotyping. Male. Mice. Mice, Inbred A. Mice, Nude. Neoplasm Transplantation. Transfection

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15768385.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 81428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


13. Bisgaard ML, Bülow S: Familial adenomatous polyposis (FAP): genotype correlation to FAP phenotype with osteomas and sebaceous cysts. Am J Med Genet A; 2006 Feb 1;140(3):200-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gardner syndrome is characterized by the triad of colorectal adenomas, soft and hard tissue tumors.
  • This disorder was regarded as a separate disease until the identification of the APC gene when it was recognized that mutations in the APC gene were the underlying cause of both Gardner syndrome and familial adenomatous polyposis (FAP).
  • The present study aimed at examining whether a particular APC genotype could be delineated in FAP patients with benign extracolonic manifestations: sebaceous cysts and/or osteomas.
  • [MeSH-minor] Bone Neoplasms / complications. DNA Mutational Analysis. Diagnosis, Differential. Epidermal Cyst / complications. Female. Gardner Syndrome / complications. Gardner Syndrome / diagnosis. Gardner Syndrome / genetics. Genotype. Humans. Male. Mutation. Osteoma / complications. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16411234.001).
  • [ISSN] 1552-4825
  • [Journal-full-title] American journal of medical genetics. Part A
  • [ISO-abbreviation] Am. J. Med. Genet. A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein
  •  go-up   go-down


14. Baatrup G, Elbrønd H, Hesselfeldt P, Wille-Jørgensen P, Møller P, Breum B, Qvist N: Rectal adenocarcinoma and transanal endoscopic microsurgery. Diagnostic challenges, indications and short term results in 142 consecutive patients. Int J Colorectal Dis; 2007 Nov;22(11):1347-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 43%of the patients, the cancer diagnosis was not recognized before TEM.
  • Eighty-five percent of all tumors were classified as benign based on macroscopic appearance; on digital rectal examination, 35% were benign, rectal ultrasound classified 15% as benign, and the preoperative biopsy was benign in 36%.
  • CONCLUSION: All larger rectal tumors should be evaluated for malignancy before treatment, even if TEM is the only surgical option, due to high age and comorbidiy.
  • When resecting large sessile tumors, there is a considerable risk of incomplete radicality.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / diagnosis. Rectal Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol Suppl. 2003;(239):34-9 [14743881.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Eur J Surg Oncol. 1986 Dec;12(4):373-7 [3780991.001]
  • [Cites] Gut. 1984 May;25(5):437-44 [6714785.001]
  • [Cites] Dig Surg. 2005;22(3):182-9; discussion 189-90 [16137996.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):974-80 [12905551.001]
  • [Cites] Colorectal Dis. 2004 May;6(3):153-7 [15109377.001]
  • [Cites] Abdom Imaging. 2003 Nov-Dec;28(6):784-93 [14753591.001]
  • [Cites] BMJ. 2003 Nov 22;327(7425):1196-201 [14630754.001]
  • [Cites] Colorectal Dis. 2002 Nov;4(6):467-72 [12790922.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):200-6 [11852333.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1380-8 [15906120.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Dec;19(6):993-1005 [16338654.001]
  • [Cites] Colorectal Dis. 2000 Sep;2(5):252-63 [23578114.001]
  • (PMID = 17643251.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


15. Gelos M, Hinderberger D, Welsing E, Belting J, Schnurr K, Mann B: Analysis of albumin fatty acid binding capacity in patients with benign and malignant colorectal diseases using electron spin resonance (ESR) spectroscopy. Int J Colorectal Dis; 2010 Jan;25(1):119-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of albumin fatty acid binding capacity in patients with benign and malignant colorectal diseases using electron spin resonance (ESR) spectroscopy.
  • INTRODUCTION: In colorectal cancer (CRC), no biological marker is known that could serve both as a marker for detection and prognosis.
  • OBJECTIVE: The aim of this study was to examine whether the FA binding to albumin is detectably and significantly altered in CRC patients when compared with patients having benign colorectal diseases.
  • MATERIALS AND METHODS: One hundred four patients operatively or endoscopically treated for CRC, sigmoid diverticulitis, or a colorectal adenoma were examined before procedure.
  • RESULTS AND DISCUSSIONS: Patients with CRC showed significantly lower DR values (DR, -0.09 +/- 0.98 vs. 0.61 +/- 1.43) than patients with benign colorectal diseases, consistent with a change of conformation and transport function of albumin in CRC.
  • Within the CRC group, with advanced tumor stage, the difference in DR values increased.
  • Furthermore, a correlation with advanced tumor stage can be established.
  • [MeSH-major] Colorectal Neoplasms / metabolism. Electron Spin Resonance Spectroscopy / methods. Fatty Acids / metabolism. Serum Albumin / metabolism
  • [MeSH-minor] Aged. Demography. Endoscopy. Female. Humans. Male. Neoplasm Staging. Postoperative Care. Preoperative Care. Protein Binding

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2003 Oct 30;425(6961):905 [14586448.001]
  • [Cites] Transfus Apher Sci. 2002 Oct;27(2):129-35 [12350048.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1935-53 [17932341.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2746-8 [15987925.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1348-60 [17512720.001]
  • [Cites] Biol Pharm Bull. 2002 Jun;25(6):695-704 [12081132.001]
  • [Cites] Cancer Invest. 2007 Sep;25(6):378-83 [17882647.001]
  • [Cites] Nat Struct Biol. 1998 Sep;5(9):827-35 [9731778.001]
  • [Cites] Bull Exp Biol Med. 2004 Aug;138(2):177-8 [15662465.001]
  • [Cites] Biochim Biophys Acta. 1990 Dec 6;1036(3):228-36 [2175216.001]
  • [Cites] Clin Chem. 2006 Nov;52(11):2129-34 [16990414.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Dis Markers. 2003-2004;19(1):1-10 [14757941.001]
  • [Cites] Biochim Biophys Acta. 2000 Jun 1;1466(1-2):350-60 [10825455.001]
  • [Cites] J Mol Biol. 2006 Aug 11;361(2):336-51 [16844140.001]
  • [Cites] Gastroenterology. 2008 Aug;135(2):380-99 [18582467.001]
  • [Cites] Angew Chem Int Ed Engl. 2004 Sep 6;43(35):4616-21 [15317002.001]
  • (PMID = 19644694.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Serum Albumin
  •  go-up   go-down


16. Ram E, Sherman Y, Weil R, Vishne T, Kravarusic D, Dreznik Z: Is mechanical bowel preparation mandatory for elective colon surgery? A prospective randomized study. Arch Surg; 2005 Mar;140(3):285-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is mechanical bowel preparation mandatory for elective colon surgery? A prospective randomized study.
  • BACKGROUND: Bowel preparation prior to colonic surgery usually includes antibiotic therapy together with mechanical bowel preparation (MBP).
  • Mechanical bowel preparation may cause discomfort to the patient, prolonged hospitalization, and water and electrolyte imbalance.
  • DESIGN AND PATIENTS: The study includes all patients who had elective large bowel resection at Campus Golda between April 1, 1999, and March 31, 2002.
  • The patients in the MBP group received Soffodex for bowel preparation.
  • Two hundred sixty-eight patients (81.5%) underwent surgery owing to colorectal cancer and 61 patients (18.5%) owing to benign disease.
  • The hospitalization period was longer in the bowel-prepared group (mean +/- SD, 8.2 +/- 5.1 days) as compared with the nonprepared group (mean +/- SD, 8.0 +/- 2.7 days).
  • The time until the first bowel movement was similar between the 2 groups: a mean +/- SD of 4.2 +/- 1.3 days in the nonprepared group as compared with a mean +/- SD of 4.3 +/- 1.1 days in the prepared group (P = NS).
  • CONCLUSION: Our results suggest that no advantage is gained by preoperative MBP in elective colorectal surgery.
  • [MeSH-minor] Aged. Colonic Diseases / surgery. Colorectal Neoplasms / surgery. Elective Surgical Procedures. Enema. Female. Humans. Length of Stay. Male. Postoperative Complications / epidemiology. Prospective Studies

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781794.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cathartics; 0 / Phosphates; SE337SVY37 / sodium phosphate
  •  go-up   go-down


17. Syrjänen KJ: Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland. Scand J Infect Dis Suppl; 2009;107:3-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to cancer of the lower female genital tract, human papillomaviruses (HPV) are associated with a large number of benign, precancer and cancer lesions at different anatomic sites in both genders.
  • Malignant tumours and their precursors are usually attributed to the oncogenic (high-risk, HR) HPV types, whereas benign lesions (papillomas) are associated with the low-risk (LR) HPV types, most notably with HPV6 and HPV11.
  • In the first step, published HPV literature was used to create a list of benign, premalignant and malignant lesions associated with this virus at different anatomic sites.
  • The evidence linking HPV to each individual tumour category was classified as:.
  • All published evidence was weighted for each individual malignant, premalignant and benign lesion, anatomic region by region, while assessing the attributable fraction of HPV6/11 genotypes in each lesion.
  • Because benign and most of the precancer lesions are not registered by FCR or GLOBOCAN, different approaches had to be used to derive the best estimates for their incidence, based on published literature or other registries (e.g. genital wart registry of the UK and Wales, and mass screening registry of FCR).
  • The malignant neoplasms with established or emerging evidence on the causal role of HPV are listed by their ICD-10 codes in Table I.
  • Included in this list are also 2 controversial malignancies (colorectal cancer and endometrial cancer), of which the contradictory HPV data are critically discussed.
  • Estimated disease burden due to HPV6/11 in Finland, calculated as numbers of annual new cases by anatomic region and tumour type is given in Table II, and summarized in Figure 1.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408160.001).
  • [ISSN] 0300-8878
  • [Journal-full-title] Scandinavian journal of infectious diseases. Supplementum
  • [ISO-abbreviation] Scand J Infect Dis Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 131
  •  go-up   go-down


18. Joyce T, Cantarella D, Isella C, Medico E, Pintzas A: A molecular signature for Epithelial to Mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis. Clin Exp Metastasis; 2009;26(6):569-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A molecular signature for Epithelial to Mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis.
  • Sporadic colorectal cancer is a major cause of death worldwide.
  • Development takes place in a sequential manner from benign adenomas leading to carcinomas.
  • We have developed a model cell system to study oncogenic Ras mutations in colorectal cancer cell lines.
  • In this analysis two Caco-2 derived cell lines expressing Ha-RasV12 (Caco-H) and Ki-RasV12 (Caco-K), respectively, have been used in large-scale microarray profiling against a Caco-2 control.
  • [MeSH-major] Colonic Neoplasms / pathology. Epithelium / pathology. Mesoderm / pathology. Oligonucleotide Array Sequence Analysis / methods

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 29;323(4):1246-50 [15451431.001]
  • [Cites] Oncogene. 2006 Jul 6;25(29):4116-21 [16491118.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):338-45 [16012517.001]
  • [Cites] Oncogene. 2007 Oct 25;26(49):6979-88 [17486063.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] Surgery. 2005 Aug;138(2):306-12 [16153441.001]
  • [Cites] Oncogene. 2007 Feb 22;26(8):1222-30 [16924233.001]
  • [Cites] Oncogene. 2005 Mar 31;24(14 ):2375-85 [15674322.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):548-58 [16098727.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5243-50 [14500354.001]
  • [Cites] Cells Tissues Organs. 2007;185(1-3):204-12 [17587826.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Oncogene. 2006 Jan 5;25(1):91-102 [16158056.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Trends Cell Biol. 2006 Jan;16(1):45-54 [16337795.001]
  • [Cites] Biochem J. 2006 Mar 1;394(Pt 2):449-57 [16232121.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3291-310 [17496923.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12 ):1816-22 [16773075.001]
  • [Cites] Gut. 2005 Sep;54(9):1283-6 [15843421.001]
  • [Cites] J Gastroenterol. 2006 Mar;41(3):185-92 [16699851.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1096-109 [17030180.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27424-31 [11309385.001]
  • [Cites] Carcinogenesis. 2004 Jan;25(1):47-59 [14555616.001]
  • [Cites] Curr Opin Drug Discov Devel. 2008 Jan;11(1):86-94 [18175271.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12 (6):488-96 [15864483.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2475-87 [10713171.001]
  • [Cites] Dev Dyn. 2001 Oct;222(2):292-300 [11668606.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3069-75 [15131045.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Int J Oncol. 2004 Nov;25(5):1495-500 [15492844.001]
  • [Cites] BMC Cancer. 2006 Jul 12;6:186 [16836752.001]
  • [Cites] Int J Cancer. 2007 Aug 15;121(4):714-23 [17455256.001]
  • [Cites] Int J Oncol. 2007 May;30(5):1273-7 [17390031.001]
  • [Cites] J Cell Biol. 2003 Nov 24;163(4):847-57 [14623871.001]
  • [Cites] Oncogene. 2008 Jun 19;27(27):3875-9 [18246119.001]
  • [Cites] Expert Opin Pharmacother. 2007 May;8(7):895-900 [17472535.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):616-27 [16152623.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1267-78 [11430829.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7792-7 [11691794.001]
  • [Cites] Med Mol Morphol. 2007 Jun;40(2):68-81 [17572842.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8070-8 [16299238.001]
  • [Cites] Cell Res. 2007 Apr;17(4):289-90 [17426696.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):947-52 [10029089.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Aug 17;360(1):109-14 [17585878.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2459-66 [17675336.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1745-56 [18098284.001]
  • (PMID = 19340593.001).
  • [ISSN] 1573-7276
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


19. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP, National Academy of Clinical Biochemistry: National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem; 2008 Dec;54(12):e11-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
  • BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed.
  • METHODS: Published reports relevant to use of tumor markers for 5 cancer sites--testicular, prostate, colorectal, breast, and ovarian--were critically reviewed.
  • RESULTS: For testicular cancer, alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. alpha-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors.
  • Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 microg/L.
  • In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease.
  • CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer.
  • CONCLUSIONS: Implementation of these recommendations should encourage optimal use of tumor markers.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. Clinical Laboratory Techniques. Colorectal Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis. Prostatic Neoplasms / diagnosis. Testicular Neoplasms / diagnosis


20. Neri E, Vagli P, Picchietti S, Vannozzi F, Linsalata S, Bardine A, Bartolozzi C: CT colonography: contrast enhancement of benign and malignant colorectal lesions versus fecal residuals. Abdom Imaging; 2005 Nov-Dec;30(6):694-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT colonography: contrast enhancement of benign and malignant colorectal lesions versus fecal residuals.
  • Mean attenuation values of benign polyps before and after contrast administration were 30 +/- 15 HU and 90 +/- 18 HU, respectively.
  • Mean attenuation values of colorectal cancer before and after contrast administration were 43 +/- 15 HU and 124 +/- 18 HU, respectively.
  • The difference in attenuation value between precontrast and postcontrast studies of polyps was statistically significant (mean 60 HU, p < 0.01); the same was true for colorectal cancer (mean 81 HU, p < 0.01).
  • The use of contrast medium could be of help in computed tomographic colonography for discriminating polypoid benign lesions and colorectal cancer from fecal residuals.
  • [MeSH-major] Colonography, Computed Tomographic / methods. Colorectal Neoplasms / radiography. Feces
  • [MeSH-minor] Colonic Polyps / radiography. Contrast Media. Diagnosis, Differential. Humans. Image Enhancement / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16252141.001).
  • [ISSN] 0942-8925
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


21. Lécuru F, Metzger U, Scarabin C, Le Frère Belda MA, Olschwang S, Laurent Puig P: Hysteroscopic findings in women at risk of HNPCC. Results of a prospective observational study. Fam Cancer; 2007;6(3):295-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Operative hysteroscopy was done in 24 cases; in two patients with apparently benign focal lesions the results showed simple hyperplasia without atypias.
  • This study led to diagnosis of endometrial simple hyperplasia in 6% of cases and of cancer in 3%.
  • [MeSH-major] Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Endometrial Hyperplasia / diagnosis. Endometrial Neoplasms / diagnosis. Hysteroscopy. Polyps / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1994 Jul-Aug;14(4B):1661-4 [7979204.001]
  • [Cites] Am J Med. 1994 Jun;96(6):516-20 [8017449.001]
  • [Cites] Anticancer Res. 1994 Jul-Aug;14(4B):1675-8 [7979205.001]
  • [Cites] Int J Clin Oncol. 2004 Aug;9(4):262-9 [15375702.001]
  • [Cites] JAMA. 2002 Oct 2;288(13):1610-21 [12350192.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):821-4 [17096354.001]
  • [Cites] N Engl J Med. 1997 Dec 18;337(25):1792-8 [9400035.001]
  • [Cites] Bull Cancer. 2004 Apr;91(4):303-15 [15242312.001]
  • [Cites] Am J Surg Pathol. 2004 Dec;28(12):1667; author reply 1667 [15577693.001]
  • [Cites] N Engl J Med. 2006 Jan 19;354(3):261-9 [16421367.001]
  • [Cites] Br J Obstet Gynaecol. 1999 Dec;106(12 ):1259-64 [10609719.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1708-12 [11920532.001]
  • [Cites] Hum Reprod. 2001 Jan;16(1):168-171 [11139557.001]
  • [Cites] Obstet Gynecol. 2003 Nov;102(5 Pt 2):1152-5 [14607039.001]
  • [Cites] BJOG. 2002 Sep;109(9):1076-8 [12269688.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):706-11 [15166662.001]
  • [Cites] Jpn J Clin Oncol. 2002 Mar;32(3):110-2 [11956307.001]
  • [Cites] Gynecol Obstet Invest. 2004;58(1):26-31 [15031622.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):677-85 [8431847.001]
  • [Cites] Ultrasound Obstet Gynecol. 1997 Jan;9(1):53-8 [9060132.001]
  • [Cites] Hum Mol Genet. 1997 Jan;6(1):105-10 [9002677.001]
  • [Cites] Int J Cancer. 2002 Nov 10;102(2):198-200 [12385019.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):74-80 [14529665.001]
  • (PMID = 17415684.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


22. Rochester M, Scurrell S, Parry JR: Prospective evaluation of a novel one-stop testicular clinic. Ann R Coll Surg Engl; 2008 Oct;90(7):565-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, it was possible for patients with unsuspected malignancy to have their diagnosis delayed.
  • Source of referral, suspected diagnosis, findings and outcome were recorded.
  • Eleven patients were suspected to have testicular tumour on ultrasound and proceeded to orchidectomy in this period.
  • CONCLUSIONS: The majority of patients passing through this clinic are the 'worried-well' with benign scrotal pathology.
  • They can now be seen within 2 weeks regardless of whether their GP suspects testicular tumour.
  • This reduces anxiety in this large group of patients freeing capacity elsewhere in the diagnostic imaging department.
  • [MeSH-minor] Adult. England. Humans. Male. Medical Audit. Orchiectomy / utilization. Prospective Studies. Referral and Consultation. Testicular Neoplasms / surgery. Treatment Outcome. Waiting Lists

  • MedlinePlus Health Information. consumer health - Testicular Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann R Coll Surg Engl. 2000 May;82(3):167-70 [10858677.001]
  • [Cites] Ann R Coll Surg Engl. 2006 Jul;88(4):363-6 [16834856.001]
  • [Cites] Int J Clin Pract. 2002 Jan-Feb;56(1):26-8 [11833552.001]
  • [Cites] Postgrad Med J. 2002 Dec;78(926):748-51 [12509694.001]
  • [Cites] J R Soc Med. 2004 Jun;97(6):279-81 [15173329.001]
  • [Cites] Clin Radiol. 1992 Dec;46(6):397-400 [1493653.001]
  • [Cites] Br J Urol. 1994 Feb;73(2):147-51 [8131015.001]
  • [Cites] Br J Urol. 1994 Feb;73(2):152-4 [8131016.001]
  • [Cites] Postgrad Med J. 1997 Mar;73(857):129-36 [9135826.001]
  • [Cites] J Urol. 1997 Aug;158(2):479-80 [9224328.001]
  • [Cites] Colorectal Dis. 2005 May;7(3):241-4 [15859961.001]
  • [Cites] Colorectal Dis. 2005 Sep;7(5):450-3 [16108880.001]
  • [Cites] Int J Clin Pract. 2005 Nov;59(11):1334-9 [16236089.001]
  • [Cites] Postgrad Med J. 2005 Nov;81(961):728-30 [16272239.001]
  • [Cites] BJU Int. 2000 Jul;86(1):87-8 [10886089.001]
  • (PMID = 18701008.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2728304
  •  go-up   go-down


23. Vibert E, Perniceni T, Levard H, Denet C, Shahri NK, Gayet B: Laparoscopic liver resection. Br J Surg; 2006 Jan;93(1):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Twenty-four laparoscopic hepatectomies (27 per cent) were for benign disease and 65 (73 per cent) for malignant tumours, including hepatocellular carcinoma (HCC) in 16 patients and colorectal metastasis (CRM) in 41.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Laparoscopy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholecystectomy, Laparoscopic / methods. Colorectal Neoplasms. Disease-Free Survival. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 British Journal of Surgery Society Ltd.
  • (PMID = 16273531.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Dursun AB, Demirag F, Bayiz H, Sertkaya D: Endobronchial metastases: a clinicopathological analysis. Respirology; 2005 Sep;10(4):510-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: It is important to distinguish endobronchial metastases (EBM) from both primary lung cancers and benign lesions, as treatment will differ.
  • Symptoms, primary tumour sites, recurrence interval, radiological and bronchoscopic features, and histopathological properties were assessed.
  • The primary tumour sites were: colorectal (4), breast (3), renal (3), lymphoma (3), rhabdomyosarcoma (2), bladder (1), thyroid (1) and malignant melanoma (1).
  • The mean time from the diagnosis of the primary tumour to their presentation was 3.89+/-1.09 (range, 0--19) years.
  • In five patients, EBM was diagnosed synchronously with their extra pulmonary primary tumour.
  • Histopathological examination revealed epithelial tissue at the surface of the tumour in nine cases and four of these were metaplastic.
  • [MeSH-major] Bronchial Neoplasms / pathology. Bronchial Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Bronchial Diseases / pathology. Bronchoscopy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16135176.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


25. DaCosta RS, Andersson H, Cirocco M, Marcon NE, Wilson BC: Autofluorescence characterisation of isolated whole crypts and primary cultured human epithelial cells from normal, hyperplastic, and adenomatous colonic mucosa. J Clin Pathol; 2005 Jul;58(7):766-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: In vivo autofluorescence endoscopic imaging and spectroscopy have been used to detect and differentiate benign (hyperplastic) and preneoplastic (adenomatous) colonic lesions.
  • This suggests that the detection of colonic epithelial fluorescence alone, if possible, may be sufficient to differentiate benign (hyperplastic) from preneoplastic and neoplastic (adenomatous) colonic intramucosal lesions during in vivo fluorescence endoscopy.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Colonic Polyps / diagnosis. Intestinal Mucosa / pathology. Precancerous Conditions / diagnosis
  • [MeSH-minor] Adenomatous Polyps / diagnosis. Cells, Cultured. Colon / pathology. Colon / ultrastructure. Diagnosis, Differential. Humans. Hyperplasia / diagnosis. Lysosomes / ultrastructure. Microscopy, Confocal. Microscopy, Electron. Microscopy, Fluorescence. Mitochondria / ultrastructure. Rhodamine 123

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc Clin N Am. 2000 Jan;10(1):37-69, vi [10618453.001]
  • [Cites] Electrophoresis. 2004 Nov;25(21-22):3740-5 [15565697.001]
  • [Cites] J Microsc. 2001 Jan;201(Pt 1):70-6 [11136441.001]
  • [Cites] J Biomed Opt. 2001 Jan;6(1):31-40 [11178578.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):642-50 [11323596.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2001 Jul;281(1):E72-80 [11404224.001]
  • [Cites] Photochem Photobiol. 2001 Jun;73(6):636-41 [11421069.001]
  • [Cites] Photochem Photobiol. 2003 Oct;78(4):384-92 [14626667.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2004 Jul;14(3):595-620, xi [15261205.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):706-13 [15362025.001]
  • [Cites] Apoptosis. 2004 Nov;9(6):749-55 [15505417.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1978 Jul;46(1):79-86 [210436.001]
  • [Cites] J Biol Chem. 1979 Jun 10;254(11):4764-71 [220260.001]
  • [Cites] J Histochem Cytochem. 1979 Jan;27(1):36-43 [220325.001]
  • [Cites] J Histochem Cytochem. 1979 Jan;27(1):44-8 [438504.001]
  • [Cites] In Vitro. 1981 May;17(5):441-9 [7019042.001]
  • [Cites] Exp Cell Res. 1982 Apr;138(2):409-17 [6210565.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Eur J Cell Biol. 1984 May;34(1):137-43 [6428888.001]
  • [Cites] J Clin Pathol. 1984 Sep;37(9):975-83 [6206100.001]
  • [Cites] In Vitro Cell Dev Biol. 1987 Jun;23(6):403-12 [3597281.001]
  • [Cites] Lasers Surg Med. 1987;7(6):467-72 [3123828.001]
  • [Cites] Br J Cancer. 1988 Mar;57(3):287-9 [2833300.001]
  • [Cites] Gastrointest Endosc. 1990 Mar-Apr;36(2):105-11 [2335276.001]
  • [Cites] Photochem Photobiol. 1991 Jun;53(6):777-86 [1653427.001]
  • [Cites] FASEB J. 1992 Jun;6(9):2726-34 [1377141.001]
  • [Cites] Lasers Surg Med. 1992;12(1):63-78 [1614265.001]
  • [Cites] Tohoku J Exp Med. 1993 Jan;169(1):1-19 [8211966.001]
  • [Cites] J Photochem Photobiol B. 1993 Sep;20(1):47-54 [8229468.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):446-54 [7513501.001]
  • [Cites] Int J Colorectal Dis. 1994 Apr;9(1):13-22 [8027618.001]
  • [Cites] Biochem J. 1994 Jul 15;301 ( Pt 2):373-7 [7519008.001]
  • [Cites] Pathol Res Pract. 1994 Apr;190(4):333-41 [8078802.001]
  • [Cites] Lasers Surg Med. 1995;16(1):48-60 [7715402.001]
  • [Cites] Scanning Microsc. 1995 Mar;9(1):149-56; discussion 156-8 [8553013.001]
  • [Cites] J Biol Chem. 1996 Feb 16;271(7):3647-51 [8631975.001]
  • [Cites] IEEE Trans Biomed Eng. 1996 Feb;43(2):113-22 [8682522.001]
  • [Cites] Gastrointest Endosc. 1996 Aug;44(2):168-76 [8858323.001]
  • [Cites] Jpn J Cancer Res. 1996 Dec;87(12):1199-203 [9045953.001]
  • [Cites] Cytometry. 1997 Jun 15;30(3):151-6 [9222101.001]
  • [Cites] Endoscopy. 1998 May;30(4):419-21 [9689519.001]
  • [Cites] J Microsc. 1998 Jul;191(Pt 1):1-7 [9723186.001]
  • [Cites] Photochem Photobiol. 1999 Mar;69(3):364-74 [10089830.001]
  • [Cites] Am J Clin Pathol. 1964 Dec;42:581-93 [14239434.001]
  • [Cites] Baillieres Best Pract Res Clin Gastroenterol. 1999 Apr;13(1):1-10 [11030629.001]
  • (PMID = 15976349.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 1N3CZ14C5O / Rhodamine 123
  • [Other-IDs] NLM/ PMC1770728
  •  go-up   go-down


26. Aqueveque A C, González E P, Gutiérrez B D, Jaimovich F R, Díaz P JC, Csendes G P, Orellana P P, Lavados M H, Alliende G I, Araya L S: [Fusion of SPECT with computed tomography or magnetic resonance for the interpretation of abnormal tracer uptake]. Rev Med Chil; 2007 Jun;135(6):725-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These were classified before and after the fusion as probably malignant or probably benign.
  • Therefore the suspicion of malignancy was presumptively confirmed in 72% of foci and fusion results would have reached a 27% of incremental diagnostic value in 14 cases that changed of category (11 with differentiated thyroid carcinoma, one with colorectal cancer, one with a nasal Ewing sarcoma and one with a brain tumor).
  • [MeSH-major] Carcinoma / diagnosis. Magnetic Resonance Imaging / methods. Radiopharmaceuticals. Thyroid Neoplasms / diagnosis. Tomography, Emission-Computed, Single-Photon / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728898.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


27. Dallaire F, Dewailly E, Rouja P: Cancer incidence and mortality rates in Bermuda. West Indian Med J; 2009 Sep;58(4):367-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For Whites, if we exclude benign skin cancers, the picture was similar with the notable exception of lung cancer being more frequent than colon/rectum in White males.
  • Rates in Bermuda were higher for cancer of the mouth, ovarian cancer (Black women), melanoma (Whites), colorectal cancer (White women) and breast cancer (White women).
  • Lung and colorectal cancers were less frequent in Bermuda's Black population.
  • [MeSH-major] Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20099779.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Jamaica
  •  go-up   go-down


28. Ramos-Valadez DI, Patel CB, Ragupathi M, Bartley Pickron T, Haas EM: Single-incision laparoscopic right hemicolectomy: safety and feasibility in a series of consecutive cases. Surg Endosc; 2010 Oct;24(10):2613-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between July 2009 and October 2009, SILC right hemicolectomy was performed for 13 consecutive, unselected patients presenting with benign or malignant pathology.
  • CONCLUSION: The SILC procedure is a safe and feasible method for benign and malignant diseases requiring a right hemicolectomy.
  • [MeSH-minor] Adult. Colonic Neoplasms / surgery. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1013-6 [18607608.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):295-8 [7795990.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):477-84 [15992696.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] J Reprod Med. 1992 Jul;37(7):588-94 [1387906.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Colorectal Dis. 2008 Oct;10(8):823-6 [18684153.001]
  • [Cites] BJU Int. 2009 May;103(9):1150-3 [19220268.001]
  • [Cites] Surg Endosc. 2010 Apr;24(4):888-90 [19760335.001]
  • [Cites] Dis Colon Rectum. 2009 May;52(5):1021-4 [19502875.001]
  • [Cites] J Reprod Med. 1992 Sep;37(9):777-84 [1453397.001]
  • [Cites] J Am Coll Surg. 2002 Sep;195(3):395-408 [12229949.001]
  • [Cites] Colorectal Dis. 2010 Jan;12(1):66-70 [19508527.001]
  • [Cites] Arch Surg. 2009 Feb;144(2):173-9; discussion 179 [19221330.001]
  • (PMID = 20364353.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


29. Alsaad KO, Serra S, Schmitt A, Perren A, Chetty R: Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix. Endocr Pathol; 2007;18(1):16-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Goblet cell carcinoid (GCC) of the vermiform appendix is an uncommon neoplasm and its histogenesis is controversial.
  • Little is known about the immunohistochemical expression of cytokeratins 7 (CK7) and 20 (CK20) in appendiceal neuroendocrine tumors.
  • The tumors were also evaluated for Ki-67 proliferation index, mitotic activity, tumor necrosis, extracellular pools of mucin, obvious intestinal type adenocarcinomatous foci, angiolymphatic permeation, perineural/neural infiltration, and the depth of invasion of the appendix wall.
  • Immunohistochemically, all 17 (100%) of GCC exhibited strong and diffuse immunopositivity for CK20, whereas expression of CK7 was present in 12 cases (70.5%), ranging from 5 to 50% of tumor cells being labeled.
  • On the other hand, 25 cases of classical carcinoid tumors were consistently negative for CK7; however, 4 cases (16%) showed immunolabeling for CK20 in 25-50% of the tumor cells.
  • In addition, GCC shows the same CK7/CK20 immunoexpression as colorectal adenocarcinoma.
  • Goblet cell carcinoid should be regarded as a crypt cell or an amphicrine carcinoma rather than a variant of carcinoid tumor, a lesion that has benign connotations.
  • [MeSH-major] Appendiceal Neoplasms / metabolism. Carcinoid Tumor / metabolism. Goblet Cells / metabolism. Keratin-20 / metabolism. Keratin-7 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Proliferation. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):188-9 [7102895.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1317-22 [14598408.001]
  • [Cites] Differentiation. 1993 Jun;53(2):75-93 [8359595.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1189-98 [14681318.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):47-58 [12114750.001]
  • [Cites] World J Surg Oncol. 2005 Jun 20;3:36 [15967038.001]
  • [Cites] Am J Surg Pathol. 1981 Apr;5(3):213-24 [7235117.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):729-38 [16253897.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):685-7 [7978019.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Histopathology. 1992 Apr;20(4):345-9 [1577412.001]
  • [Cites] Histopathology. 2003 Feb;42(2):137-40 [12558745.001]
  • [Cites] Eur J Surg Oncol. 1992 Aug;18(4):386-7 [1521632.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):370-6 [16485156.001]
  • [Cites] Surg Today. 2000;30(1):78-81 [10648090.001]
  • [Cites] Cancer. 1979 Nov;44(5):1700-6 [498041.001]
  • [Cites] Ann Anat Pathol (Paris). 1969 Oct-Dec;14(4):393-406 [5378353.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):869-70 [7490325.001]
  • [Cites] Cancer. 1974 Aug;34(2):338-44 [4852178.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):386-90 [11231488.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):524-9 [15998383.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):14-21 [10391558.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):271-6 [15551743.001]
  • (PMID = 17652796.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Keratin-7; 0 / Ki-67 Antigen
  •  go-up   go-down


30. Whitehouse PA, Tilney HS, Armitage JN, Simson JN: Transanal endoscopic microsurgery: risk factors for local recurrence of benign rectal adenomas. Colorectal Dis; 2006 Nov;8(9):795-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery: risk factors for local recurrence of benign rectal adenomas.
  • OBJECTIVE: Transanal endoscopic microsurgery (TEM) is a minimally invasive technique for excision of selected benign and malignant rectal neoplasms.
  • It is considered a safe and effective treatment but recurrence rates of 1-13% are reported for benign lesions.
  • The aim of this study was to assess risk factors for local recurrence of benign rectal lesions and to evaluate mortality and morbidity following TEM.
  • METHOD: Data were prospectively collected from all patients undergoing TEM for benign adenomas from January 1998 to March 2005.
  • CONCLUSION: TEM is a safe and effective treatment for benign rectal adenomas.
  • [MeSH-major] Adenoma / surgery. Endoscopy / methods. Microsurgery / methods. Neoplasm Recurrence, Local. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2006 Nov;8(9):731-2 [17032317.001]
  • (PMID = 17032328.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Yang BL, Shao WJ, Sun GD, Chen YQ, Huang JC: Perianal mucinous adenocarcinoma arising from chronic anorectal fistulae: a review from single institution. Int J Colorectal Dis; 2009 Sep;24(9):1001-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Such lesions can be misdiagnosed for the more common benign perianal abscess or fistula.
  • One patient with inguinal lymph node metastases died due to distant metastasis 6 months after diagnosis.
  • Although radical resection of the tumour with abdominoperineal resection remains the surgical treatment of choice.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Anus Neoplasms / etiology. Rectal Fistula / complications

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2006 May;49(5):668-78 [16583292.001]
  • [Cites] Tech Coloproctol. 2006 Mar;10(1):51-3 [16528482.001]
  • [Cites] AJR Am J Roentgenol. 2006 Aug;187(2):517-21 [16861558.001]
  • [Cites] Oncology. 1993 Nov-Dec;50(6):495-9 [8233293.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1348-60 [17512720.001]
  • [Cites] Radiology. 2006 Apr;239(1):18-33 [16567481.001]
  • [Cites] Surg Today. 1996;26(9):707-10 [8883243.001]
  • [Cites] Tech Coloproctol. 2007 Mar;11(1):34-8 [17357864.001]
  • [Cites] Surg Today. 2008;38(6):555-8 [18516539.001]
  • [Cites] Dig Surg. 2003;20(1):69-71 [12637812.001]
  • [Cites] Dis Colon Rectum. 1985 May;28(5):361-6 [3158499.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1061-7 [18418652.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s138-40 [15655599.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Tech Coloproctol. 2006 Oct;10 (3):249-52 [16969607.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1274-83 [12873671.001]
  • [Cites] Rev Esp Enferm Dig. 2006 Apr;98(4):310-2 [16792461.001]
  • [Cites] Am Surg. 1996 Dec;62(12):1000-2 [8955235.001]
  • [Cites] Am Surg. 2003 Feb;69(2):166-9 [12641361.001]
  • [Cites] Eur Radiol. 2003 Aug;13(8):2053-4 [12942309.001]
  • (PMID = 19205706.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


32. Kontzoglou K, Moulakakis KG, Alexiou D, Safioleas MC, Nikiteas N, Giahnaki AE, Kyroudes A, Kostakis A, Karakitsos P: The role of liquid-based cytology in the investigation of colorectal lesions: a cytohistopathological correlation and evaluation of diagnostic accuracy. Langenbecks Arch Surg; 2007 Mar;392(2):189-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of liquid-based cytology in the investigation of colorectal lesions: a cytohistopathological correlation and evaluation of diagnostic accuracy.
  • BACKGROUND AND AIMS: The role of cytologic techniques is not widely accepted even if it is well documented that the cytologic investigation of colorectal tract could complement the biopsy and increase the correct diagnosis of carcinomas.
  • This study aims to evaluate the role of Thin-Prep(R) liquid-based cytology in the investigation of colorectal lesions.
  • Based on the final diagnosis, 89 out of 93 total malignant cases and 53 out of 53 total benign cases were correctly diagnosed with Thin-Prep(R) technique (four false negatives).
  • Accurate diagnosis with biopsy was performed in 87 out of 93 total malignant cases and 53 out of 53 total benign cases with biopsy (six false negatives).
  • CONCLUSIONS: Liquid-based cytology appears to be an easy, highly accurate, and reliable cytologic method for the diagnostic approach of colorectal diseases and could be applied as complementary to biopsy for the improvement of the diagnosis.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Colorectal Neoplasms / pathology. Cytodiagnosis / methods. Microtomy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1996 Jul-Aug;40(4):669-75 [8693884.001]
  • [Cites] Acta Cytol. 1996 Sep-Oct;40(5):895-9 [8842163.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):163-7 [8607439.001]
  • [Cites] Acta Cytol. 1990 Sep-Oct;34(5):620-6 [2220240.001]
  • [Cites] J Surg Oncol. 1999 May;71(1):46-9 [10362091.001]
  • [Cites] Cancer. 1978 Dec;42(6):2849-53 [728879.001]
  • [Cites] S Afr Med J. 1979 Apr 14;55(16):619-23 [462273.001]
  • [Cites] Acta Cytol. 1997 Jul-Aug;41(4):1167-70 [9250316.001]
  • [Cites] Mod Pathol. 1996 Mar;9(3):304-6 [8685232.001]
  • [Cites] Acta Cytol. 2000 Jan-Feb;44(1):46-50 [10667159.001]
  • [Cites] Acta Cytol. 2002 Jul-Aug;46(4):693-6 [12146033.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2504-9 [6291742.001]
  • [Cites] Mod Pathol. 1995 Apr;8(3):270-4 [7617653.001]
  • [Cites] Diagn Cytopathol. 1997 Apr;16(4):368-71 [9143834.001]
  • [Cites] Gastrointest Endosc. 1972 Nov;19(2):77-8 [4648832.001]
  • [Cites] Singapore Med J. 2000 Dec;41(12):575-8 [11296781.001]
  • [Cites] Diagn Cytopathol. 1998 Jan;18(1):24-32 [9451555.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):609-13 [9152193.001]
  • [Cites] Diagn Cytopathol. 2001 Feb;24(2):137-41 [11169896.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1563-7 [2208009.001]
  • [Cites] Gastrointest Endosc. 1987 Oct;33(5):370-1 [3678764.001]
  • [Cites] Gut. 1991 Jul;32(7):745-8 [1855680.001]
  • (PMID = 17294213.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Uchiyama K, Ueno M, Ozawa S, Kiriyama S, Shigekawa Y, Yamaue H: Combined use of contrast-enhanced intraoperative ultrasonography and a fluorescence navigation system for identifying hepatic metastases. World J Surg; 2010 Dec;34(12):2953-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The purpose of this study was to assess the concomitant use of contrast-enhanced intraoperative ultrasound (CE-IOUS) using the new microbubble agent Sonazoid, and to assess the fluorescence navigation system (Photo Dynamic Eye, or PDE) using indocyanine green (ICG) as a novel tool for identifying colorectal metastatic lesions compared with preoperative contrast-enhanced multiple row-detected computed tomography (MDCT) and gadoxetic acid-enhanced MRI.
  • METHODS: Thirty-two patients who underwent a liver resection for colorectal metastatic carcinoma from 2008 to 2009 were included in the present study.
  • RESULTS: A total of 56 lesions were identified based on the histopathological findings of the biopsies and resected tissues; of these, 52 were confirmed to be metastases, whereas 4 were benign tumors.
  • [MeSH-major] Colorectal Neoplasms / pathology. Contrast Media. Fluorescent Dyes. Liver Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Surg. 2009 Oct;35(10 ):1495-8 [19674039.001]
  • [Cites] AJR Am J Roentgenol. 2009 Jun;192(6):1675-81 [19457834.001]
  • [Cites] AJR Am J Roentgenol. 2009 Jan;192(1):180-7 [19098199.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):236-40 [16432357.001]
  • [Cites] World J Gastroenterol. 2007 Feb 28;13(8):1252-6 [17451209.001]
  • [Cites] J Ultrasound Med. 2009 Sep;28(9):1133-42 [19710210.001]
  • [Cites] J Surg Oncol. 2009 Jul 1;100(1):75-9 [19301311.001]
  • [Cites] Ann Surg Oncol. 2010 Jan;17(1):144-51 [19774415.001]
  • [Cites] J Ultrasound Med. 2009 Apr;28(4):439-48 [19321671.001]
  • [Cites] Jpn J Radiol. 2009 May;27(4):185-93 [19499310.001]
  • [Cites] Dig Surg. 2009;26(5):392-9 [19923827.001]
  • [Cites] Cancer. 2009 Jun 1;115(11):2491-504 [19326450.001]
  • [Cites] World J Surg. 2008 Aug;32(8):1763-7 [18543027.001]
  • [Cites] World J Gastroenterol. 2008 May 28;14 (20):3207-11 [18506927.001]
  • [Cites] Br J Surg. 2009 Nov;96(11):1289-94 [19847873.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14 (4):1347-55 [17253105.001]
  • [Cites] Dig Dis. 2009;27(2):114-24 [19546549.001]
  • (PMID = 20734045.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Ferric Compounds; 0 / Fluorescent Dyes; 0 / Oxides; 0 / Sonazoid; 0 / gadolinium ethoxybenzyl DTPA; E1UOL152H7 / Iron; IX6J1063HV / Indocyanine Green; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


34. Beattie GC, Paul I, Calvert CH: Endoscopic transanal resection of rectal tumours using a urological resectoscope--still has a role in selected patients. Colorectal Dis; 2005 Jan;7(1):47-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A urological resectoscope can be safely and repeatedly used to resect advanced primary or locally recurrent rectal tumours by colorectal surgeons with urological expertise.
  • The majority (30; 70%) of resections were carried out in patients with benign disease, with 13 (30%) in patients with rectal adenocarcinoma.
  • No patients with benign disease subsequently developed an invasive carcinoma.
  • CONCLUSIONS: Accepting that this technique provides limited histopathological information regarding extent of resection and tumour clearance, our experience demonstrates that ETAR of rectal tumours using the urological resectoscope can provide a minimally invasive, effective and safe means of treating and palliating patients with benign and malignant rectal disease.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma, Villous / surgery. Anal Canal / surgery. Proctoscopy. Rectal Neoplasms / surgery. Urologic Surgical Procedures / instrumentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606584.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Bertelsen CA, Meisner S, West F, Wille-Jørgensen PA: [Treatment of colorectal obstruction with self-expanding metal stents]. Ugeskr Laeger; 2006 Feb 27;168(9):907-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of colorectal obstruction with self-expanding metal stents].
  • INTRODUCTION: Self-expanding metal stents (SEMS) serve as a bridge to surgery in cases of acute colorectal obstruction and provide palliation without surgery in patients with severe co-morbidity or disseminated disease.
  • We describe our experiences with the use of SEMS in colorectal obstruction.
  • In 11 patients the stricture was caused by benign pathology.
  • In 11 cases of benign strictures, only 4 were successful.
  • CONCLUSION: SEMS is a safe, effective procedure in the treatment of colorectal obstruction.
  • In our experience, stenting of benign strictures is ineffective and associated with higher rates of complications.
  • [MeSH-major] Colonic Diseases / therapy. Colorectal Neoplasms / therapy. Intestinal Obstruction / therapy. Rectal Diseases / therapy. Stents


36. Uygur-Bayramicli O, Dabak R, Orbay E, Dolapcioglu C, Sargin M, Kilicoglu G, Guleryuzlu Y, Mayadagli A: Type 2 diabetes mellitus and CA 19-9 levels. World J Gastroenterol; 2007 Oct 28;13(40):5357-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: CA 19-9 is a tumor-associated antigen, which is elevated in pancreatic, upper gastrointestinal tract, ovarian hepatocellular, and colorectal cancers, as well as in inflammatory conditions of the hepatobiliary system, biliary obstruction and in thyroid diseases.
  • CA 19-9 is used in the diagnosis of pancreatic cancer but is also a marker of pancreatic tissue damage that might be caused by diabetes.
  • We propose that a higher cut-off value of CA 19-9 should be used in diabetics to differentiate benign and malignant pancreatic disease, and subtle elevations of CA 19-9 in diabetics should be considered as the indication of exocrine pancreatic dysfunction.
  • [MeSH-major] CA-19-9 Antigen / blood. Diabetes Mellitus, Type 2 / immunology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / immunology


37. Cera SM, Wexner SD: Minimally invasive treatment of colon cancer. Cancer J; 2005 Jan-Feb;11(1):26-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The advantages of laparoscopy in the treatment of benign diseases have been well demonstrated.
  • Since 1991, several concerns have limited the widespread use of laparoscopy for attempted cure of colorectal carcinoma.
  • This review aims to analyze the results of several studies published to date on short and long term outcome of laparoscopy for colorectal carcinoma, based on levels of evidence.
  • [MeSH-major] Carcinoma / surgery. Colonic Neoplasms / surgery. Laparoscopy / methods. Postoperative Complications

  • MedlinePlus Health Information. consumer health - After Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15831221.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


38. Sasaki A, Nitta H, Otsuka K, Takahara T, Nishizuka S, Wakabayashi G: Ten-year experience of totally laparoscopic liver resection in a single institution. Br J Surg; 2009 Mar;96(3):274-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between May 1997 and April 2008, 82 patients underwent TLLR for hepatocellular carcinoma (HCC) (37 patients), liver metastases (39) and benign liver lesions (six).
  • Nine patients underwent simultaneous laparoscopic resection of colorectal primary cancer and synchronous liver metastases.
  • Median tumour size and surgical margin were 25 (range 15-85) and 6 (range 0-40) mm respectively.
  • The overall 5-year survival rate after surgery for HCC and colorectal metastases was 53 and 64 per cent respectively.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Laparoscopy. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Complications / etiology. Length of Stay. Liver Diseases / surgery. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications / etiology. Survival Analysis

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224518.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Spinelli P, Calarco G, Mancini A, Ni XG: Operative colonoscopy in cancer patients. Minim Invasive Ther Allied Technol; 2006;15(6):339-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is not only a diagnostic tool, but it also allows some interventional treatments in benign and malignant digestive diseases.
  • Operative colonoscopy has been used to perform curative treatment of various kinds of polyps, flat and carpet-like adenomas and early colorectal carcinomas.
  • Endoscopic palliative treatment strategies, such as the placement of self-expandable metal stents (SEMS), laser ablation, photodynamic therapy (PDT), argon plasma coagulation (APC), electrocoagulation, and injection therapy, have been proved to effectively alleviate advanced colorectal cancer (CRC) associated symptoms and maintain or improve the quality of the patient's remaining life.
  • [MeSH-major] Colonoscopy / methods. Colorectal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17190658.001).
  • [ISSN] 1364-5706
  • [Journal-full-title] Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  • [ISO-abbreviation] Minim Invasive Ther Allied Technol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 44
  •  go-up   go-down


40. De Chiara L, Rodríguez-Piñeiro AM, Cordero OJ, Rodríguez-Berrocal FJ, Ayude D, Rivas-Hervada And FJ, de la Cadena MP: Soluble CD26 levels and its association to epidemiologic parameters in a sample population. Dis Markers; 2009;27(6):311-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Previous studies have suggested the use of soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas.
  • The aim of this study was to assess the sCD26 concentration in a large cohort to evaluate its association to epidemiologic parameters and CRC-related symptoms/pathologies.
  • However, sCD26 was related to non-inflammatory benign pathologies (excluding rectal bleeding, changes in bowel habits, haemorrhoids, diverticula) and to inflammatory benign pathologies.
  • DISCUSSION: Our results confirm that the sCD26 can be easily offered and evaluated in a large cohort.
  • Additionally, the validation of sCD26 as a tumour marker for screening and case-finding purposes requires a further comparison with an established non-invasive test like the faecal occult blood.
  • [MeSH-minor] Adult. Age Factors. Aged. Biomarkers / blood. Cohort Studies. Colorectal Neoplasms / blood. Colorectal Neoplasms / epidemiology. Diverticulum / blood. Diverticulum / epidemiology. Female. Fissure in Ano / blood. Fissure in Ano / epidemiology. Gastrointestinal Hemorrhage / blood. Gastrointestinal Hemorrhage / epidemiology. Gastrointestinal Tract / pathology. Gastrointestinal Tract / physiopathology. Hemorrhoids / blood. Hemorrhoids / epidemiology. Humans. Inflammation / blood. Inflammation / epidemiology. Intestinal Polyps / blood. Intestinal Polyps / epidemiology. Irritable Bowel Syndrome / blood. Irritable Bowel Syndrome / epidemiology. Male. Middle Aged. Rectum / pathology. Rectum / physiopathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20075514.001).
  • [ISSN] 1875-8630
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers; EC 3.4.14.5 / DPP4 protein, human; EC 3.4.14.5 / Dipeptidyl Peptidase 4
  • [Other-IDs] NLM/ PMC3835055
  •  go-up   go-down


41. Kazaryan AM, Pavlik Marangos I, Rosseland AR, Røsok BI, Mala T, Villanger O, Mathisen O, Giercksky KE, Edwin B: Laparoscopic liver resection for malignant and benign lesions: ten-year Norwegian single-center experience. Arch Surg; 2010 Jan;145(1):34-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic liver resection for malignant and benign lesions: ten-year Norwegian single-center experience.
  • BACKGROUND: The introduction of laparoscopic liver resection has been challenging because new and safe surgical techniques have had to be developed, and skepticism remains about the use of laparoscopy for malignant neoplasms.
  • We present herein a large-volume single-center experience with laparoscopic liver resection.
  • One hundred thirteen patients had malignant lesions, of whom 96 had colorectal metastases.
  • INTERVENTION: Laparoscopic liver resection for malignant and benign lesions.
  • Tumor-free resection margins determined by histopathologic evaluation were achieved in 140 of 149 malignant specimens (94.0%).
  • The 5-year actuarial survival for patients undergoing procedures for colorectal metastases was 46%.
  • Perioperative morbidity and mortality and long-term survival after laparoscopic resection of colorectal metastases appear to be comparable to those after open resections.
  • [MeSH-major] Colorectal Neoplasms / surgery. Hepatectomy / methods. Liver Diseases / surgery. Liver Neoplasms / surgery


42. Pencavel TD, Strauss DC, Thomas GP, Thomas JM, Hayes AJ: Does the two-week rule pathway improve the diagnosis of soft tissue sarcoma? A retrospective review of referral patterns and outcomes over five years in a regional sarcoma centre. Ann R Coll Surg Engl; 2010 Jul;92(5):417-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the two-week rule pathway improve the diagnosis of soft tissue sarcoma? A retrospective review of referral patterns and outcomes over five years in a regional sarcoma centre.
  • The final histological diagnosis of patients referred on the basis of the two-week guidelines are documented.
  • Twelve patients referred under the two-week rule were proved to have sarcoma, nine after specific investigations including imaging or histological diagnosis.
  • There has not been a commensurate rise in the detection of sarcoma or, more specifically, diagnosis of the deep sarcomas associated with worse prognosis.
  • Current clinical guidelines have essentially had no impact on the early diagnosis and treatment of soft tissue sarcoma, and may negatively impact on the treatment of patients with proven sarcoma by delaying treatment within a regional centre because of redirection of a large number of patients with benign abnormalities to such centres.
  • [MeSH-major] Referral and Consultation / standards. Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Early Diagnosis. Guideline Adherence. Health Services Research / methods. Humans. London. Outcome Assessment (Health Care). Practice Guidelines as Topic. Retrospective Studies. State Medicine / standards. State Medicine / statistics & numerical data. Time Factors. Workload / statistics & numerical data

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):443-8 [15837054.001]
  • [Cites] Ann R Coll Surg Engl. 2005 May;87(3):171-3 [15901376.001]
  • [Cites] BMJ. 2005 Sep 17;331(7517):590 [16166112.001]
  • [Cites] BMJ. 2007 Aug 11;335(7614):288 [17631514.001]
  • [Cites] Colorectal Dis. 2007 Oct;9(8):758 [17655721.001]
  • [Cites] Ann R Coll Surg Engl. 2008 Jan;90(1):69-71 [18201506.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Ann R Coll Surg Engl. 2009 Mar;91(2):106-9 [19102819.001]
  • [Cites] Clin Radiol. 2009 Jun;64(6):615-21 [19414084.001]
  • [Cites] Eur J Cancer. 2009 Aug;45(12):2091-102 [19351580.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):492-6 [12888818.001]
  • [Cites] Acta Orthop Scand. 1981 Jun;52(3):287-93 [7282321.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii89-93 [18456783.001]
  • (PMID = 20487596.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3180317
  •  go-up   go-down


43. Raje D, Mukhtar H, Oshowo A, Ingham Clark C: What proportion of patients referred to secondary care with iron deficiency anemia have colon cancer? Dis Colon Rectum; 2007 Aug;50(8):1211-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is an impression that because this presentation is nonspecific it may be associated with a longer delay from referral to diagnosis compared with those patients with symptoms of change in bowel habit and/or rectal bleeding caused by more distal colorectal cancer.
  • The underlying diagnosis reached for each patient was determined by using ICD10 C18-21.
  • Case note review confirmed the diagnoses and yielded information on urgency of referral and time to diagnosis.
  • Other patients with iron deficiency anemia were found to have benign upper or lower gastrointestinal disease (n = 125) or upper gastrointestinal cancer (n = 1).
  • The mean delay from referral to diagnosis for these was 31 days for those referred urgently but 60 days for those referred routinely.
  • [MeSH-major] Anemia, Iron-Deficiency / etiology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / epidemiology


44. Pillinger SH, Monson JR: Laparoscopy for colorectal malignancy. Dig Surg; 2005;22(1-2):34-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy for colorectal malignancy.
  • Laparoscopy for colorectal pathology is technically demanding with a steep learning curve.
  • In expert hands, there is no doubt that there is a place for laparoscopy in the operative armamentarium for the treatment of benign disease.
  • The evidence available suggests that laparoscopic resection is a feasible and appropriate option for the treatment of colorectal carcinoma.
  • [MeSH-major] Colorectal Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Anastomosis, Surgical. Clinical Competence. Humans. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838169.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 82
  •  go-up   go-down


45. Brankovic B, Radisavljevic M, Radojkovic M, Stanojevic G, Stojanovic M, Nagorni A, Radojkovic D, Jeremic L, Nestorovic M, Karamarkovic A: Nonfunctional retroperitoneal paraganglioma presenting as acute upper gastrointestinal hemorrhage. Hepatogastroenterology; 2010 Mar-Apr;57(98):288-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Paragangliomas are very rare tumors arising from extraadrenal chromaffin cells.
  • Clinical presentation of benign retroperitoneal nonfunctional paraganglioma is unspecific.
  • Symptoms may occur when tumor attains a remarkable size or when complications arise.
  • This article reports a case of nonfunctional retroperitoneal paraganglioma as a cause of acute upper gastrointestinal hemorrhage which represents the unusual urgent clinical manifestation of these tumors.
  • The presented case emphasizes the necessity to include extraadrenal paraganglioma in the differential diagnosis in all patients with retroperitoneal mass found even in the presence of at first appearance non-related emergency condition like acute upper gastrointestinal bleeding.
  • [MeSH-major] Gastrointestinal Hemorrhage / diagnosis. Paraganglioma / diagnosis. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583429.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


46. Singhi AD, Montgomery EA: Colorectal granular cell tumor: a clinicopathologic study of 26 cases. Am J Surg Pathol; 2010 Aug;34(8):1186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal granular cell tumor: a clinicopathologic study of 26 cases.
  • Granular cell tumor (GCT) is commonly located in the subcutaneous tissue and oral cavity, and uncommon in the gastrointestinal tract, in which the majority arises in the esophagus with over-representation in African Americans (AA).
  • We report the clinicopathologic features of 1 of the largest series to date of colorectal GCTs.
  • We reviewed the clinical features of 26 colorectal GCTs seen at our institution between the years 1995 to 2009, which included 24 biopsies, 1 low anterior resection, and 1 colectomy.
  • The majority of colorectal GCT involved the right colon (19/26, 73%) ranging in size from 0.2 to 1.8 cm (mean 0.6 cm).
  • Most neoplasms were encountered on routine colonoscopy (14/24, 64%), however 3 patients presented with hematochezia, 3 with changing bowel habits, 2 with Crohn disease, 1 with diverticular disease, and 1 with appendicitis.
  • Of the 20 cases available for histologic review, the tumors were noted to either be infiltrative (12/20, 60%) or marginated (8/20, 40%) involving either the mucosa (7/20, 35%), submucosa (10/20, 50%), or both (3/20, 15%).
  • The microscopic features were similar to those of GCTs found elsewhere, but many of the neoplasms differed by displaying nuclear pleomorphism (8/20, 40%), lymphoid cuffs (9/20, 45%), and focal calcification (7/20, 35%).
  • On immunochemistry, 18 of the neoplasms were stained for S-100 and all cases showed positive staining.
  • Although infrequently found in the colorectum, colorectal GCT typically presents incidentally on routine colonoscopy and involves the right colon; it is not over-represented in AA patients.
  • GCTs can have both an infiltrative or marginated growth pattern with a subset displaying nuclear pleomorphism, a lymphoid cuff, focal calcification, and reactive mucosal surface changes, which in our experience, may lead to misdiagnosis on colorectal mucosal biopsies.
  • Although GCTs were benign tumors in this series, if incompletely excised regrowth of the lesion may occur and therefore, follow-up may be warranted.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy. Colectomy. Colonoscopy. Female. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. S100 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661017.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


47. Gopalan A, Sharp DS, Fine SW, Tickoo SK, Herr HW, Reuter VE, Olgac S: Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol; 2009 May;33(5):659-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: We reviewed histologic material and clinical data from 24 cases selected from a database of 67 dome-based tumors diagnosed and treated at our institution from 1984 to 2005.
  • RESULT: The mean age at diagnosis was 52 years (range: 26 to 68 y).
  • In all instances but 1, cystitis cystica/glandularis was focal and predominantly in the bladder overlying the urachal neoplasm.
  • Urachal remnants were identified in 15 cases: the urachal epithelium was benign urothelial-type in 6 cases and showed adenomatous changes in 9.
  • In all 3, urachal remnants were identified and showed transition from benign to adenomatous epithelium.
  • On immunohistochemistry, these tumors were positive for CK20 and variably positive for CK7 and 34BE12.
  • Surface urothelial involvement by carcinoma and presence of cystitis cystica/glandularis do not necessarily exclude the diagnosis of urachal carcinoma.
  • Immunostains do not unequivocally discriminate a urachal from a colorectal carcinoma, but diffuse positivity for 34BE12 would support, and diffuse nuclear immunoreactivity for beta-catenin would militate against, a diagnosis of urachal carcinoma.
  • Local recurrence may be owing to seeding within the distal urothelial tract, particularly in tumors with a configuration that is polypoid and which open into the bladder cavity.
  • [MeSH-major] Carcinoma / pathology. Urachus / pathology. Urinary Bladder Neoplasms / pathology. Urothelium / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Signet Ring Cell / pathology. Chemotherapy, Adjuvant. Cystectomy. Cystitis / pathology. Databases as Topic. Female. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant. Treatment Outcome. Umbilicus / surgery. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1380-7 [11684954.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2434-40 [17932892.001]
  • [Cites] J Urol. 2003 Apr;169(4):1295-8 [12629346.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):456-9 [15043458.001]
  • [Cites] J Urol. 1982 Jan;127(1):40-2 [7057501.001]
  • [Cites] Urology. 1983 Apr;21(4):360-6 [6836822.001]
  • [Cites] J Urol. 1984 Jan;131(1):1-8 [6361280.001]
  • [Cites] Urol Res. 1983;11(5):235-8 [6659216.001]
  • [Cites] Urology. 1985 Sep;26(3):218-21 [4035835.001]
  • [Cites] J Urol. 1986 Jun;135(6):1240-4 [3712579.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2165-72 [1706216.001]
  • [Cites] J Urol. 1994 Feb;151(2):365-6 [8283526.001]
  • [Cites] Hum Pathol. 1996 Mar;27(3):240-7 [8600037.001]
  • [Cites] Cancer. 1955 Jul-Aug;8(4):741-58 [13240656.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1217-22 [15803184.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):69-87 [16512600.001]
  • [Cites] J Urol. 2006 Jun;175(6):2042-7; discussion 2047 [16697798.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):712-20 [16826585.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):721-8 [16826584.001]
  • [Cites] J Urol. 2007 Jul;178(1):74-8; discussion 78 [17499279.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • (PMID = 19252435.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / beta Catenin
  • [Other-IDs] NLM/ NIHMS627175; NLM/ PMC4225778
  •  go-up   go-down


48. Wong SC, Chan CM, Ma BB, Hui EP, Ng SS, Lai PB, Cheung MT, Lo ES, Chan AK, Lam MY, Au TC, Chan AT: Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res; 2009 Feb 1;15(3):1005-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients.
  • PURPOSE: Current immunomagnetic enrichment method can only detect general epithelial antigens of circulating tumor cells (CTC).
  • Further characterization of the CTCs to provide specific information on the tumor type is not possible.
  • We attempted to overcome this drawback by developing the methodology for using a gastrointestinal-specific anti-cytokeratin (CK) 20 antibody to detect CTCs in colorectal cancer patients' blood.
  • EXPERIMENTAL DESIGN: The protocol was validated using a colorectal cancer SW480 cell line.
  • The clinical significance of findings in colorectal cancer was investigated by detecting CK20-positive CTCs (pCTC) in patients with colorectal cancer, other common cancers, colorectal adenoma, benign colorectal diseases, and normal subjects.
  • Moreover, the malignant nature of CK20 pCTCs was examined by comparing chromosome 17 aberration patterns with those from the corresponding primary tumors.
  • When applied in patient samples, the detection rates were 62% (132 colorectal cancer patients; median number = 11 CTCs), 0% (120 patients with other common cancers), 6% (50 colorectal adenoma patients), 0% (120 patients with benign colorectal diseases), and 0% (40 normal subjects).
  • Furthermore, statistical analysis showed that CK20 pCTC numbers were associated with tumor-node-metastasis stage and lymph node status.
  • Using the median CK20 pCTC numbers as the cutoff points, stratified groups of colorectal cancer patients had significant differences in their recurrence, metastasis, and survival.
  • Finally, chromosome 17 aneusomy in 90% of colorectal cancer patients with CK20 pCTCs matched with those from the primary tumors.
  • CONCLUSIONS: Detection of CK20 pCTCs using the new protocol could generate clinically important information for colorectal cancer patients.
  • [MeSH-major] Colorectal Neoplasms / blood. Immunomagnetic Separation / methods. Keratin-20 / blood. Neoplastic Cells, Circulating / chemistry
  • [MeSH-minor] Adenoma / blood. Biomarkers, Tumor / blood. Cell Line, Tumor. Chromosomes, Human, Pair 17. Humans. Prognosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188172.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20
  •  go-up   go-down


49. van Baardewijk LJ, Idenburg FJ, Clahsen PC, Möllers MJ: [Von Meyenburg complexes in the liver: not metastases]. Ned Tijdschr Geneeskd; 2010;154:A1674
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VMCs, also called biliary hamartomas, are rare and benign malformations of the bile ducts.
  • Intraoperative frozen section analysis to differentiate between malignant and benign lesions has a sensitivity of 97% and a specificity of 99%.
  • The benign nature of VMCs means that they do not require treatment.
  • The patient underwent total mesorectal excision and follow-up after 3, 7 and 9 months did not reveal any indications of recurrent colorectal cancer or metastases.
  • [MeSH-major] Hamartoma / diagnosis. Liver Diseases / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Aged. Bile Ducts / abnormalities. Bile Ducts / pathology. Carcinoma / pathology. Carcinoma / surgery. Diagnosis, Differential. Female. Humans. Incidental Findings. Liver / pathology. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20619020.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


50. Chautard J, Alves A, Zalinski S, Bretagnol F, Valleur P, Panis Y: Laparoscopic colorectal surgery in elderly patients: a matched case-control study in 178 patients. J Am Coll Surg; 2008 Feb;206(2):255-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colorectal surgery in elderly patients: a matched case-control study in 178 patients.
  • BACKGROUND: We conducted a prospective case-matched study to compare outcomes of laparoscopic colorectal surgery in elderly (>or= 70 years) and younger (< 70 years) patients.
  • STUDY DESIGN: Among 506 consecutive patients who underwent 536 colorectal resections supervised by 1 colorectal surgeon (YP), 75 elderly patients (>or= 70 years)were matched with 103 younger patients (< 70 years), according to gender, body mass index, pathology, and surgical procedure.
  • RESULTS: One hundred seventy-eight patients (95 men and 83 women) underwent laparoscopic colorectal resection for colorectal carcinoma (40%) or benign diseases (60%).
  • CONCLUSIONS: This large case-matched study suggested that laparoscopic colorectal surgery may be proposed in elderly patients, with similar postoperative outcomes as this surgery has in young patients, despite significantly more frequent cardiorespiratory comorbidities.
  • [MeSH-major] Age Factors. Colectomy. Colorectal Neoplasms / surgery. Laparoscopy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Coll Surg. 2008 Jul;207(1):141-2 [18589378.001]
  • (PMID = 18222377.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Todaro L, Christiansen S, Varela M, Campodónico P, Pallotta MG, Lastiri J, Sacerdote de Lustig E, Bal de Kier Joffé E, Puricelli L: Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol; 2007 Jun;83(2):135-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors.
  • We studied by Western blot the pattern of serum NCAM bands in patients with gliomas (n = 34), with brain metastasis of different primary cancers (n = 27) and with benign brain tumors (n = 22)] compared with healthy controls (n = 69).
  • A similar pattern was found in patients with brain metastasis or brain benign tumors, suggesting that the pattern of serum NCAM bands would be useful to detect brain tumor pathology.
  • Interestingly, we found that 9/12 patients with glioma showed a significant decrease in NCAM HMW/LMW ratio between 1-3 months after successful tumor removal.
  • Thus, serum NCAM could be a useful marker for monitoring treatment.NCAM expression was also analyzed at tissular level in 59 glioma sections from paraffined tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Glioma / metabolism. Neural Cell Adhesion Molecules / metabolism
  • [MeSH-minor] Adult. Aged. Brain / metabolism. Case-Control Studies. Female. Gene Expression Profiling. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Melanoma / metabolism. Melanoma / secondary. Middle Aged. Protein Isoforms. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Statistics, Nonparametric. Survival Analysis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1267-76 [9777989.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):106-10 [9662259.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):330-3 [1821250.001]
  • [Cites] Prostate. 1997 Aug 1;32(3):214-20 [9254901.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Dec 10;74(1-2):69-82 [10640677.001]
  • [Cites] J Neurochem. 1989 Nov;53(5):1372-8 [2795005.001]
  • [Cites] Surgery. 2001 Nov;130(5):834-43 [11685193.001]
  • [Cites] Int J Dev Neurosci. 1993 Oct;11(5):681-90 [8116479.001]
  • [Cites] Int J Cancer. 1994 Jul 1;58(1):116-22 [8014007.001]
  • [Cites] Pancreas. 2001 Mar;22(2):122-5 [11249065.001]
  • [Cites] Int J Colorectal Dis. 2005 Jan;20(1):57-61 [15309466.001]
  • [Cites] Semin Cell Biol. 1992 Jun;3(3):189-97 [1623208.001]
  • [Cites] J Neurosci Res. 1995 May 1;41(1):49-64 [7674377.001]
  • [Cites] J Neurooncol. 2001 Feb;51(3):245-64 [11407596.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):2020-8 [9581848.001]
  • [Cites] Int J Dev Neurosci. 2000 Apr-Jun;18(2-3):193-9 [10715574.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):978-80 [16126882.001]
  • [Cites] Neuropathol Appl Neurobiol. 1991 Jun;17(3):207-17 [1891065.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):283-92 [11839780.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1227-30 [9137477.001]
  • [Cites] Cell. 1988 Dec 23;55(6):955-64 [3203385.001]
  • [Cites] Br J Haematol. 2005 May;129(4):539-41 [15877737.001]
  • [Cites] J Zhejiang Univ Sci B. 2005 Jan;6(1):4-10 [15593384.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6364-70 [2400996.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38305-16 [16172115.001]
  • [Cites] J Neurosci Res. 1999 Jan 1;55(1):99-106 [9890438.001]
  • [Cites] Front Biosci. 2003 May 01;8:d900-11 [12700044.001]
  • [Cites] Prog Neurobiol. 1998 Aug;55(6):659-69 [9670224.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:425-56 [9442880.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):607-13 [15627025.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):485-94 [16212813.001]
  • [Cites] Neuroimmunomodulation. 1997 Mar-Apr;4(2):57-61 [9483195.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):207-16 [12507300.001]
  • [Cites] Oncology. 2005;69 Suppl 1:14-6 [16210871.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):415-21 [10821486.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):6942-6 [3863135.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):125-8 [12086870.001]
  • [Cites] Neurobiol Dis. 2004 Mar;15(2):387-93 [15006709.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Glycobiology. 2005 Sep;15(9):887-94 [15872150.001]
  • [Cites] Biol Psychiatry. 1998 May 1;43(9):680-6 [9583002.001]
  • [Cites] Acta Neurol Belg. 2004 Dec;104(4):148-53 [15742604.001]
  • [Cites] Cancer. 1998 May 15;82(10):1921-31 [9587126.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jan;65(1):1-11 [16410743.001]
  • (PMID = 17216340.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecules; 0 / Protein Isoforms
  •  go-up   go-down


52. Cho JY, Han HS, Yoon YS, Shin SH: Experiences of laparoscopic liver resection including lesions in the posterosuperior segments of the liver. Surg Endosc; 2008 Nov;22(11):2344-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The indications for resection were hepatocellular carcinoma (n = 57), hepatolithiasis (n = 39), liver metastasis from colorectal cancer (n = 21), and benign liver tumor (n = 11).
  • [MeSH-minor] Chi-Square Distribution. Female. Humans. Liver Neoplasms / surgery. Male. Middle Aged. Retrospective Studies. Statistics, Nonparametric. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2007 Nov;21(11):2004-11 [17705086.001]
  • [Cites] Am J Surg. 2005 Feb;189(2):190-4 [15720988.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):31-7 [10400033.001]
  • [Cites] Surg Endosc. 2005 Jul;19(7):886-91 [15920694.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(1):1-8 [10982584.001]
  • [Cites] Br J Surg. 2003 Jun;90(6):644-6 [12808610.001]
  • [Cites] Br J Surg. 2007 Jan;94(1):58-63 [17054316.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):90-7 [12131090.001]
  • [Cites] Surg Endosc. 2003 Dec;17(12):1914-8 [14574547.001]
  • [Cites] J Am Coll Surg. 2007 Dec;205(6):816-8 [18035269.001]
  • [Cites] Arch Surg. 2003 Jul;138(7):763-9; discussion 769 [12860758.001]
  • [Cites] Hepatology. 2006 Dec;44(6):1694-700 [17133494.001]
  • [Cites] Br J Surg. 2006 Jan;93(1):67-72 [16273531.001]
  • [Cites] J Pediatr Surg. 2006 Jan;41(1):e25-8 [16410084.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2006 Jun;16(3):274-7 [16796440.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2006 Feb;16(1):32-5 [16552376.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):753-62 [11088070.001]
  • [Cites] Surgery. 2007 Feb;141(2):203-211 [17263977.001]
  • [Cites] Surg Endosc. 2007 Apr;21(4):619-24 [17285378.001]
  • [Cites] Ann Surg. 1994 Dec;220(6):711-9 [7986136.001]
  • [Cites] Surgery. 1996 Sep;120(3):468-75 [8784399.001]
  • [Cites] J Am Coll Surg. 2003 Feb;196(2):236-42 [12595052.001]
  • (PMID = 18528623.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


53. Biyikoğlu I, Oztürk ZA, Köklü S, Babali A, Akay H, Filik L, Basat O, Ozer H, Ozer E: Primary anorectal malignant melanoma: two case reports and review of the literature. Clin Colorectal Cancer; 2007 May;6(7):532-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anorectal melanoma is a very rare tumor with poor prognosis because of delay in diagnosis.
  • It is often mistaken for benign conditions such as hemorrhoids or rectal polyps.
  • [MeSH-major] Melanoma / secondary. Rectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17553203.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Laisaar T, Vooder T, Umbleja T: Thoracoscopic resection of a solitary pulmonary nodule in patients with a known history of malignancy. Thorac Cardiovasc Surg; 2008 Oct;56(7):418-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, a definite diagnosis should be established.
  • Lung wedge resection was performed to establish the morphological diagnosis.
  • RESULTS: Among our 34 patients (17 male and 17 female with a median age of 67.5 years), the most common primary cancers were colorectal (n = 12) and kidney (n = 6).
  • Twenty-two patients (65 %) had lung metastases and 12 (35 %) had benign nodules.
  • [MeSH-major] Lung Neoplasms / surgery. Neoplasms, Second Primary / surgery. Solitary Pulmonary Nodule / surgery. Thoracic Surgery, Video-Assisted

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18810700.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


55. Garrean S, Hering J, Saied A, Jani J, Espat NJ: Gastric adenocarcinoma arising from fundic gland polyps in a patient with familial adenomatous polyposis syndrome. Am Surg; 2008 Jan;74(1):79-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Familial adenomatous polyposis (FAP) is a rare hereditary syndrome characterized by multiple colorectal polyps and early development of colorectal cancer.
  • Although FAP uniformly involves the large bowel, it may also produce lesions in the stomach and upper intestinal tract.
  • In the general population, these polyps are considered benign and have no malignant potential.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenomatous Polyposis Coli / pathology. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology


56. Toll A, Real FX: Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next? Cell Cycle; 2008 Sep 1;7(17):2674-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next?
  • Somatic oncogenic activating mutations in FGFR3 and/or PIK3CA have recently been described in benign epithelial cutaneous lesions that never progress to malignancy (seborrheic keratoses and epidermal nevi).
  • The same mutations have been observed in malignant neoplasms from other tissues (bladder carcinoma, cervix cancer, colorectal cancer, myeloma).
  • However, many of the abovementioned epithelial benign cutaneous tumors do not harbour mutations in FGFR3 or PIK3CA.
  • [MeSH-major] Mutation / genetics. Skin Neoplasms / genetics. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728396.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 82
  •  go-up   go-down


57. Ben QW, Zhao Z, Ge SF, Zhou J, Yuan F, Yuan YZ: Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. Int J Oncol; 2009 Mar;34(3):821-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating levels of periostin may help identify patients with more aggressive colorectal cancer.
  • Elevated levels of periostin have been implicated as playing important roles in tumor invasion and metastasis in various tissues.
  • Thus, we determined whether serum periostin levels were associated with progression and poor prognosis in colorectal cancer (CRC) patients.
  • The serum levels of periostin in CRC patients (40.9+/-15.4 ng/ml) were significantly elevated compared to that in healthy volunteers (21.0+/-7.3 ng/ml, P<0.0001) and benign colorectal polyps or adenomas (22.4+/-8.5 ng/ml, P<0.0001).
  • Periostin may be produced by the stromal cells surrounding the tumor, but not by the CRC cells themselves.
  • [MeSH-major] Biomarkers, Tumor / blood. Cell Adhesion Molecules / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212687.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / RNA, Messenger
  •  go-up   go-down


58. Krouse R, Grant M, Ferrell B, Dean G, Nelson R, Chu D: Quality of life outcomes in 599 cancer and non-cancer patients with colostomies. J Surg Res; 2007 Mar;138(1):79-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reports have described QOL outcomes in cancer patients with colostomies and inflammatory bowel syndrome with colostomies, but little has been written regarding a comparison of cancer and non-cancer populations.
  • Most were results from cancer (517/599), with colorectal cancer being the most common diagnosis.
  • The most common benign diagnoses were inflammatory bowel disease and diverticulitis.
  • While patients with cancer had a better overall QOL than those with benign processes, concerns were common to all colostomy patients.
  • [MeSH-major] Colorectal Neoplasms / psychology. Colostomy / psychology. Inflammatory Bowel Diseases / psychology. Quality of Life

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196990.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 33572; United States / NCI NIH HHS / CA / CA 72666
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


59. Avoranta T, Sundström J, Korkeila E, Syrjänen K, Pyrhönen S, Laine J: The expression and distribution of group IIA phospholipase A2 in human colorectal tumours. Virchows Arch; 2010 Dec;457(6):659-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression and distribution of group IIA phospholipase A2 in human colorectal tumours.
  • The expression profile of this protein, however, is controversial in colorectal carcinoma.
  • The aim of this study was to examine the distribution and expression of IIA PLA2 protein in benign, premalignant and malignant colorectal tumours as well as in peritumoural mucosa.
  • Seven hyperplastic polyps, 24 adenomas and 83 colorectal carcinomas were stained with immunohistochemistry (IHC) for IIA PLA2.
  • A total of 79% of adenomas and 31% of carcinomas showed IIA PLA2-immunopositive tumour cells in IHC, and the expression was localised to epithelial cells with ISH.
  • Our results suggest that the IIA PLA2 protein content is dramatically decreased in malignant colorectal tumours as compared with adenomas.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Colorectal Neoplasms / metabolism. Group II Phospholipases A2 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Inflammation. 1993 Aug;17 (4):453-64 [8406689.001]
  • [Cites] Cell. 1995 Jun 16;81(6):957-66 [7781071.001]
  • [Cites] Front Biosci. 2008 May 01;13:4144-74 [18508504.001]
  • [Cites] J Carcinog. 2009;8:5 [19332896.001]
  • [Cites] J Biochem. 1992 Sep;112(3):350-4 [1429522.001]
  • [Cites] J Immunol. 1999 Jun 15;162(12 ):7402-8 [10358193.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):212-20 [15475936.001]
  • [Cites] Carcinogenesis. 2009 Mar;30(3):377-86 [19136477.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16203-8 [12456890.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):130-6 [12591965.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12 ):3857-61 [11751475.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2636-43 [15805260.001]
  • [Cites] Ann Oncol. 2009 Jul;20(7):1230-5 [19276398.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98 (7):3935-9 [11274413.001]
  • [Cites] Cancer Res. 1990 Nov 15;50(22):7232-5 [1977517.001]
  • [Cites] Nat Genet. 1997 Sep;17 (1):88-91 [9288104.001]
  • [Cites] J Infect Dis. 2002 Jun 15;185(12 ):1767-72 [12085323.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5184-6 [7585570.001]
  • [Cites] Drug Discov Today. 2003 Aug 1;8(15):710-6 [12927514.001]
  • [Cites] Mol Carcinog. 2007 Feb;46(2):106-16 [17091473.001]
  • [Cites] Am J Gastroenterol. 1999 Mar;94(3):713-20 [10086656.001]
  • [Cites] Oncogene. 1998 Oct 15;17 (15):2009-12 [9788445.001]
  • [Cites] Clin Chem. 1992 Sep;38(9):1824-9 [1526020.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):500-3 [9458096.001]
  • [Cites] Cancer Lett. 2006 Nov 18;243(2):255-63 [16458424.001]
  • [Cites] Adv Exp Med Biol. 1990;275:17-34 [2239445.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1084-91 [10706128.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11280-5 [11005842.001]
  • [Cites] Clin Infect Dis. 1993 Nov;17 (5):864-70 [8286627.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):545-8 [11520087.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92 (2):289-92 [9040208.001]
  • [Cites] Oncogene. 2000 Jun 29;19(28):3182-92 [10918573.001]
  • [Cites] J Rheumatol. 1993 Feb;20(2):325-30 [8474071.001]
  • [Cites] APMIS. 2009 Mar;117(3):151-61 [19245588.001]
  • [Cites] Cell. 1993 Nov 19;75(4):631-9 [8242739.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2009 Jul-Aug;57(4):291-4 [19578817.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):667-71 [11839587.001]
  • [Cites] Gut. 1997 Jan;40(1):95-101 [9155583.001]
  • [Cites] Biochim Biophys Acta. 1998 May 27;1403(1):47-56 [9622592.001]
  • [Cites] Biochim Biophys Acta. 2005 Apr 15;1733(2-3):210-23 [15863368.001]
  • [Cites] Lab Invest. 1995 Feb;72 (2):201-8 [7853853.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5A):3179-85 [17970059.001]
  • [Cites] World J Gastroenterol. 2009 Dec 21;15(47):5898-906 [20014453.001]
  • [Cites] Gut. 1994 Nov;35(11):1593-8 [7828979.001]
  • [Cites] APMIS. 1998 Aug;106(8):780-4 [9744764.001]
  • (PMID = 20938784.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.1.1.4 / Group II Phospholipases A2
  •  go-up   go-down


60. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM: Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol; 2007 Mar;20(3):375-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer.
  • Aberrant expression of human leukocyte antigen G (HLA-G) has been proposed to be involved in tumor escape mechanisms.
  • It has been also proposed that detection of HLA-G might service as a potential biomarker for diagnosis or prediction of the clinical outcomes in ovarian and breast cancers, carcinoma of the lung and endometrial cancer.
  • The aim of this current study is to determine if HLA-G is expressed in colorectal carcinomas and if the expression is associated with clinicopathological and prognostic data.
  • The expression of HLA-G was investigated immunohistochemically in 201 patients with colorectal carcinomas.
  • In this prospectively study, HLA-G protein expression was observed in 64.6% (130/201) of the primary site colorectal carcinomas, but not in the normal colorectal tissues or benign adenomas.
  • HLA-G expression in the tumors was significantly correlated with the depth of invasion, histological grade, host immune response, lymph nodal metastasis and clinical stages of the disease (P=0.001, 0.0001, 0.002, 0.001 and 0.031, respectively).
  • Patients with HLA-G positive tumors had a significantly shorter survival time than those patients with tumors that were HLA-G negative (P=0.0001).
  • Therefore, it can be gathered that HLA-G might serve as an independent prognostic factor for colorectal cancer patients.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis
  • [MeSH-minor] Female. HLA-G Antigens. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277760.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


61. Pickhardt PJ, Kim DH, Meiners RJ, Wyatt KS, Hanson ME, Barlow DS, Cullen PA, Remtulla RA, Cash BD: Colorectal and extracolonic cancers detected at screening CT colonography in 10,286 asymptomatic adults. Radiology; 2010 Apr;255(1):83-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal and extracolonic cancers detected at screening CT colonography in 10,286 asymptomatic adults.
  • PURPOSE: To retrospectively determine the detection rates, clinical stages, and short-term patient survival for all unsuspected cancers identified at screening computed tomographic (CT) colonography, including both colorectal carcinoma (CRC) and extracolonic malignancies.
  • MATERIALS AND METHODS: From April 2004 through March 2008, prospective colorectal and extracolonic interpretation was performed in 10,286 outpatient adults (5388 men, 4898 women; mean age, 59.8 years) undergoing screening CT colonography at two centers in this institutional review board-approved, HIPAA-compliant study.
  • Benign neoplasms (including advanced colorectal adenomas), symptomatic lesions, and tumors without pathologic proof were excluded.
  • Extracolonic malignancies included renal cell carcinoma (n = 11), lung cancer (n = 8), non-Hodgkin lymphoma (n = 6), and a variety of other tumors (n = 11).
  • [MeSH-major] Colonography, Computed Tomographic. Colorectal Neoplasms / diagnostic imaging
  • [MeSH-minor] Adenoma / diagnostic imaging. Adenoma / pathology. Female. Humans. Kidney Neoplasms / diagnostic imaging. Kidney Neoplasms / pathology. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / pathology. Lymphatic Metastasis. Lymphoma, Non-Hodgkin / diagnostic imaging. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplasms, Multiple Primary / diagnostic imaging. Neoplasms, Multiple Primary / pathology. Radiographic Image Interpretation, Computer-Assisted. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2010
  • (PMID = 20308446.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA144835
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


62. Silva AC, Vens EA, Hara AK, Fletcher JG, Fidler JL, Johnson CD: Evaluation of benign and malignant rectal lesions with CT colonography and endoscopic correlation. Radiographics; 2006 Jul-Aug;26(4):1085-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of benign and malignant rectal lesions with CT colonography and endoscopic correlation.
  • Colorectal carcinoma is a significant cause of death from cancer in the United States, and early detection and treatment are critical.
  • Computed tomographic (CT) colonography is a noninvasive, rapidly evolving technique that is a potential alternative to conventional colonoscopy for colorectal cancer screening.
  • [MeSH-major] Colonography, Computed Tomographic / methods. Image Enhancement / methods. Proctoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / radiography

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2006
  • (PMID = 16844933.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


63. Glasgow SC, Birnbaum EH, Lowney JK, Fleshman JW, Kodner IJ, Mutch DG, Lewin S, Mutch MG, Dietz DW: Retrorectal tumors: a diagnostic and therapeutic challenge. Dis Colon Rectum; 2005 Aug;48(8):1581-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrorectal tumors: a diagnostic and therapeutic challenge.
  • PURPOSE: Tumors occurring in the retrorectal space are heterogeneous and uncommon.
  • This study examined the diagnosis, treatment, and outcome of retrorectal tumors at a tertiary referral center.
  • METHODS: Patients with primary, extramucosal neoplasms occurring in the retrorectal space were identified using a prospectively maintained, procedural database of all adult colorectal surgical patients (1981-2003).
  • Exclusion criteria included inflammatory processes, locally advanced colorectal cancer, and metastatic malignancy.
  • RESULTS: Thirty-four patients with retrorectal tumors were treated.
  • Malignant tumors comprised 21 percent.
  • Accuracy of magnetic resonance vs. computed tomographic imaging for specific histologic tumor type was 28 vs. 18 percent, respectively.
  • All benign tumors were resected with normal histologic margins and none recurred (median follow-up, 22 months).
  • CONCLUSIONS: Retrorectal tumors remain a diagnostic and therapeutic challenge.
  • Various imaging modalities are useful for planning resection but cannot establish a definitive diagnosis.
  • Whereas benign retrorectal tumors can be completely resected, curative resection of malignant retrorectal tumors remains difficult.
  • [MeSH-major] Rectal Neoplasms / diagnosis
  • [MeSH-minor] Abdomen / surgery. Adult. Age Factors. Aged. Aged, 80 and over. Blood Loss, Surgical. Blood Transfusion. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Perineum / surgery. Proctoscopy. Prospective Studies. Rectum / surgery. Retrospective Studies. Sex Factors. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937630.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Gravante G, Delogu D, Venditti D: Colosigmoid adenocarcinoma anastomotic recurrence seeding into a transsphincteric fistula-in-ano: a clinical report and literature review. Surg Laparosc Endosc Percutan Tech; 2008 Aug;18(4):407-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the case of a left colon adenocarcinoma anastomotic recurrence that metastasized to a benign transsphincteric fistula-in-ano, presumably through the implantation of viable malignant cells shed from the secondary tumor, and discuss the implications of these findings in colorectal cancer surgery.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasm Recurrence, Local / pathology. Neoplasm Seeding. Rectal Fistula / pathology. Rectal Neoplasms / secondary. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716545.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


65. He Q, Zhang P, Zou L, Li H, Wang X, Zhou S, Fornander T, Skog S: Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep; 2005 Oct;14(4):1013-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
  • Activity of thymidine kinase 1 in serum (STK) is a useful marker for leukaemia and lymphoma, but not for solid tumors.
  • We investigate thymidine kinase 1 concentration in serum (S-TK1) as a potential tumor marker.
  • S-TK1 concentration and STK activity levels were determined in 9 human malignant diseases (breast, gastric, rectal, colorectal, lung, brain cancer, hepatoma, lymphoma, leukaemia) and in benign and non-cancerous diseases, representing 850 preoperative cases.
  • S-TK1 concentrations and STK activity levels in preoperative malignant patients were significantly higher than in healthy individuals, in patients with benign tumors and in those with non-cancerous diseases.
  • Significant correlations between concentration and activity level were only found in healthy individuals, in patients with benign tumors, and in some patients with malignancies, i.e. leukaemia, and breast and gastric cancers.
  • We conclude that S-TK1 concentration is a more sensitive tumor marker in solid malignancies than is STK activity.
  • [MeSH-major] Biomarkers, Tumor. Neoplasms / blood. Neoplasms / diagnosis. Thymidine Kinase / blood
  • [MeSH-minor] Breast Neoplasms / pathology. Cell Line, Tumor. Cell Proliferation. Dose-Response Relationship, Drug. Female. Humans. Male. Neoplasm Staging. Radioimmunoassay / methods. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142366.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.1.21 / thymidine kinase 1
  •  go-up   go-down


66. Coenegrachts K, Ghekiere J, Denolin V, Gabriele B, Hérigault G, Haspeslagh M, Daled P, Bipat S, Stoker J, Rigauts H: Perfusion maps of the whole liver based on high temporal and spatial resolution contrast-enhanced MRI (4D THRIVE): feasibility and initial results in focal liver lesions. Eur J Radiol; 2010 Jun;74(3):529-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Fifteen patients suspected for colorectal liver metastases (LMs) were included.
  • Qualitative rather than quantitative analysis was accurate for differentiating malignant and benign FLLs.
  • [MeSH-major] Algorithms. Colorectal Neoplasms / pathology. Image Interpretation, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Magnetic Resonance Angiography / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19375256.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


67. Byrne AM, Foran E, Sharma R, Davies A, Mahon C, O'Sullivan J, O'Donoghue D, Kelleher D, Long A: Bile acids modulate the Golgi membrane fission process via a protein kinase Ceta and protein kinase D-dependent pathway in colonic epithelial cells. Carcinogenesis; 2010 Apr;31(4):737-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analysis of Golgi architecture in vivo using tissue microarrays revealed Golgi fragmentation in UC and colorectal cancer tissue.
  • This represents a potential mechanism of observed chemopreventive effects of UDCA in benign and malignant disease of the colon.
  • [MeSH-minor] Colitis, Ulcerative / pathology. Colonic Neoplasms / pathology. Deoxycholic Acid / pharmacology. Dexamethasone / pharmacology. HCT116 Cells. Humans. Phosphorylation. Receptors, Glucocorticoid / physiology. Ursodeoxycholic Acid / pharmacology

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20093383.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Receptors, Glucocorticoid; 005990WHZZ / Deoxycholic Acid; 724L30Y2QR / Ursodeoxycholic Acid; 7S5I7G3JQL / Dexamethasone; EC 2.7.1.- / protein kinase C eta; EC 2.7.10.- / protein kinase D; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


68. Terzi C, Unek T, Sağol O, Yilmaz T, Füzün M, Sökmen S, Ergör G, Küpelioğlu A: Is rectal washout necessary in anterior resection for rectal cancer? A prospective clinical study. World J Surg; 2006 Feb;30(2):233-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Implantation of exfoliated malignant cells has been suggested as a possible mechanism of tumor recurrence in colorectal anastomoses that might be prevented by cytocidal washout.
  • The fluid was then classified as "acellular," "malignant cells identified," or "benign cells identified" by pathologists.
  • There is a need for a randomized, controlled, large-scale, multicenter trial to establish the clinical relevance of intraoperative rectal washout.
  • [MeSH-major] Colectomy / methods. Neoplasm Recurrence, Local / prevention & control. Neoplasm Seeding. Peritoneal Lavage / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Anastomosis, Surgical. Female. Follow-Up Studies. Humans. Intraoperative Care / methods. Male. Middle Aged. Neoplasm Staging. Probability. Prospective Studies. Reference Values. Risk Assessment. Sensitivity and Specificity. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Dec 1;52(11):1986-92 [6354419.001]
  • [Cites] Aust N Z J Surg. 1965 Feb;34:178-87 [14271060.001]
  • [Cites] Ann R Coll Surg Engl. 1979 Jul;61(4):251-7 [382965.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):602 [4027530.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1050-2 [7648150.001]
  • [Cites] Ann R Coll Surg Engl. 1989 Jan;71(1):54-6 [2923422.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):411-23 [15875292.001]
  • [Cites] Br J Surg. 1987 Nov;74(11):1049-52 [3690235.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):800-11 [9637543.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Surg Gynecol Obstet. 1988 Apr;166(4):357 [3353834.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):659-63 [6478151.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1710-2 [11156455.001]
  • [Cites] Dis Colon Rectum. 1985 Mar;28(3):164-7 [3971822.001]
  • [Cites] Acta Chir Belg. 1994 Sep-Oct;94(5):258-62 [7976066.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):389-402 [12626917.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):664-5 [6478153.001]
  • [Cites] Br J Surg. 2002 Feb;89(2):206-7 [11856135.001]
  • [Cites] Dis Colon Rectum. 1985 Apr;28(4):260-1 [3979229.001]
  • [Cites] Dis Colon Rectum. 1992 Mar;35(3):238-41 [1740068.001]
  • [Cites] Br J Surg. 1989 Apr;76(4):331-4 [2541860.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):291-6 [14991490.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1127-33 [9749496.001]
  • [Cites] Surg Today. 1997;27(5):457-9 [9130352.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Ann Med. 1997 Apr;29(2):91-3 [9187224.001]
  • [Cites] Dis Colon Rectum. 1998 Nov;41(11):1432-4 [9823812.001]
  • [Cites] Br J Surg. 1984 Feb;71(2):98-100 [6692125.001]
  • [Cites] Br J Surg. 1982 May;69(5):275-6 [7074339.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • (PMID = 16425079.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Davidson T, Goitein O, Avigdor A, Zwas ST, Goshen E: 18F- FDG-PET/CT for the diagnosis of tumor thrombosis. Isr Med Assoc J; 2009 Feb;11(2):69-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F- FDG-PET/CT for the diagnosis of tumor thrombosis.
  • BACKGROUND: Venous thromboembolism is a well-recognized and relatively frequent complication of malignancy, whereas tumor thrombosis is a rare complication of solid cancers.
  • The correct diagnosis of tumor thrombosis and its differentiation from VTE can alter patient management and prevent unnecessary long-term anticoagulation treatment.
  • OBJECTIVES: To evaluate the contribution of 18F-fluorodeoxyglucose positron emission tomography/computed tomography to the diagnosis of tumor thrombosis and its differentiation from VTE.
  • METHODS: PET/CT scans from 11 patients with suspected tumor thrombosis were retrospectively evaluated.
  • RESULTS: Eight occult tumor thromboses were identified by PET/CT-positive scans.
  • Underlying pathologies included pancreatic, colorectal, renal cell, and head-neck squamous cell carcinoma, as well as lymphoma (4 patients).
  • Accuracy of PET/CT to differentiate between tumor thrombosis and benign VTE was 100% in this small study.
  • It appears that PET/CT may be helpful in the diagnosis of occult tumor thrombosis and its differentiation from VTE.
  • [MeSH-major] Neoplastic Cells, Circulating. Positron-Emission Tomography. Thromboembolism / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Carcinoma / radiography. Carcinoma / radionuclide imaging. Cohort Studies. Diagnosis, Differential. Digestive System Neoplasms / radiography. Digestive System Neoplasms / radionuclide imaging. Female. Fluorodeoxyglucose F18. Humans. Kidney Neoplasms / radiography. Kidney Neoplasms / radionuclide imaging. Lymphoma / radiography. Lymphoma / radionuclide imaging. Male. Middle Aged. Predictive Value of Tests. Radiopharmaceuticals. Retrospective Studies

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432032.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


70. Hodder RJ, Ballal M, Selvachandran SN, Cade D: Variations in the evaluation of colorectal cancer risk. Colorectal Dis; 2005 May;7(3):254-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations in the evaluation of colorectal cancer risk.
  • SUBJECTS AND METHODS: Forty-three clinicians were each asked to assess 40 symptomatic colorectal referrals.
  • RESULTS: There was a wide degree of variation among all clinicians grading both benign and malignant disease with the overall correct classification of 54% (P-value of <0.001).
  • On average, the clinicians correctly diagnosed 71.3% of the cancer patients as compared to 44% of the benign patients.
  • Of the cancer patients, 47% were correctly classified as an urgent referral whilst 52% of the benign patients were over classified and graded as an urgent referral.
  • The mean number chosen by clinicians to have a flexible sigmoidoscopy as the appropriate first investigation was 13 (of 40 patients); this was despite the diagnosis being possible in all cases with a flexible sigmoidoscopy.
  • [MeSH-major] Carcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Practice Patterns, Physicians'. Referral and Consultation / standards

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. Barium sulfate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859964.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


71. Hemingway DM, Jameson J, Kelly MJ, Leicester Colorectal Specialist Interest Group Project Steering Committee: Straight to test: introduction of a city-wide protocol driven investigation of suspected colorectal cancer. Colorectal Dis; 2006 May;8(4):289-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Straight to test: introduction of a city-wide protocol driven investigation of suspected colorectal cancer.
  • OBJECTIVE: To decrease waiting times for colorectal cancer diagnosis.
  • RESULTS: In 2001, before the pilot only 116/188 (62%) of our colorectal cancers who were referred either under the 2-week-wait arrangements or on a 'soon' basis were diagnosed within 31 days of referral.
  • In the pilot, all colorectal cancers were diagnosed within 31 days of referral, and 95% of all diagnoses (no abnormality or benign disease) were reached within 31 days of referral.
  • After full implementation 19/19 (100%) of our cancers coming through our protocol system were diagnosed within 31 days and 95% of patients with benign disease.
  • CONCLUSION: Follow-up audit of our system one and two years later shows that we now diagnose approximately 80% of our colorectal cancers who are referred under the 2 week wait or as 'soon' referrals within 31 days.
  • [MeSH-major] Clinical Protocols. Colorectal Neoplasms / diagnosis. Primary Health Care. Referral and Consultation / organization & administration. Urban Health Services
  • [MeSH-minor] Early Diagnosis. Great Britain. Humans. Pilot Projects. Program Evaluation. Time Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630232.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Wierzbicki PM, Adrych K, Kartanowicz D, Dobrowolski S, Stanislawowski M, Chybicki J, Godlewski J, Korybalski B, Smoczynski M, Kmiec Z: Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer. J Physiol Pharmacol; 2009 Oct;60 Suppl 4:63-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer.
  • AIM: To investigate loss of heterozygosity (LOH) at FRA3B, expression of FHIT gene at the mRNA and protein levels in sporadic colorectal carcinoma (CRC) and benign colon adenoma.
  • MATERIALS AND METHODS: FHIT mRNA was quantified by the validated realtime PCR (QPCR) in tumor samples of 84 CRC patients and mucosal biopsies of 15 adenomas, in comparison to 37 control patients, whereas subgroup of 57 CRC, 10 adenoma and 10 control cases were selected for immunohistochemical (IHC) detection of the native FHIT protein and LOH determination at FRA3B.
  • CONCLUSION: Our data suggest that reduction or absence of the FHIT gene expression is not a prerequisite for colorectal cancer development and progression.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Adenoma / metabolism. Colorectal Neoplasms / metabolism. Neoplasm Proteins / biosynthesis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20083853.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / fragile histidine triad protein; 63231-63-0 / RNA; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


73. Buell JF, Cherqui D, Geller DA, O'Rourke N, Iannitti D, Dagher I, Koffron AJ, Thomas M, Gayet B, Han HS, Wakabayashi G, Belli G, Kaneko H, Ker CG, Scatton O, Laurent A, Abdalla EK, Chaudhury P, Dutson E, Gamblin C, D'Angelica M, Nagorney D, Testa G, Labow D, Manas D, Poon RT, Nelson H, Martin R, Clary B, Pinson WC, Martinie J, Vauthey JN, Goldstein R, Roayaie S, Barlet D, Espat J, Abecassis M, Rees M, Fong Y, McMasters KM, Broelsch C, Busuttil R, Belghiti J, Strasberg S, Chari RS, World Consensus Conference on Laparoscopic Surgery: The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg; 2009 Nov;250(5):825-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for surgery for benign hepatic lesions should not be widened simply because the surgery can be done laparoscopically.
  • Although data presented on colorectal metastases did not reveal an adverse effect of the laparoscopic approach on oncological outcomes in terms of margins or survival, adequacy of margins and ability to detect occult lesions are concerns.
  • [MeSH-minor] Humans. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Liver Transplantation. Living Donors. Minimally Invasive Surgical Procedures. Patient Selection. Tissue and Organ Harvesting

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19916210.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


74. Collinson RJ, McC Mortensen NJ: 'How I do it': TEM for tumors of the rectum. J Gastrointest Surg; 2009 Feb;13(2):359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'How I do it': TEM for tumors of the rectum.
  • INTRODUCTION: Transanal endoscopic microsurgery (TEM) has an established role in the management of benign rectal tumors.
  • It also has an expanding role in the management of malignant tumors, which is more demanding for the clinician.
  • This paper discusses our institutional approach to TEM for benign and malignant tumors and covers some of the current management controversies.
  • [MeSH-major] Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):429-37 [15747069.001]
  • [Cites] Dis Colon Rectum. 2002 May;45(5):601-4 [12004207.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1286-95 [7497841.001]
  • [Cites] Endoscopy. 1985 Jan;17(1):31-5 [3971938.001]
  • [Cites] Dig Surg. 2006;23(1-2):12-22 [16675907.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Int J Colorectal Dis. 2001 Nov;16(6):370-6 [11760898.001]
  • [Cites] Surg Endosc. 2006 Aug;20(8):1203-7 [16703429.001]
  • [Cites] Rev Esp Enferm Dig. 2006 Apr;98(4):234-40 [16792452.001]
  • [Cites] Br J Surg. 2007 May;94(5):627-33 [17335125.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):177-81 [7851173.001]
  • [Cites] Int J Colorectal Dis. 1986 Apr;1(2):79-84 [3611938.001]
  • [Cites] Colorectal Dis. 2000 Sep;2(5):252-63 [23578114.001]
  • [Cites] Dis Colon Rectum. 2001 Sep;44(9):1345-61 [11584215.001]
  • (PMID = 18461419.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Strunk H, Börner N, Stuckmann G, Hadizadeh D: [Pitfalls in contrast-enhanced liver sonography: consequences for the practice]. Radiologe; 2005 Jun;45(6):529-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been reported that malignant liver tumors can be differentiated from benign entities with almost 100% sensitivity and that diagnosis of the type is possible with an accuracy of over 90%.
  • [MeSH-major] Contrast Media. Diagnostic Errors / prevention & control. Image Enhancement / methods. Liver Neoplasms / diagnostic imaging. Liver Neoplasms / secondary. Microbubbles. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiol Med. 2004 Mar;107(3):174-86; quiz 187-8 [15031683.001]
  • [Cites] Radiology. 2004 Aug;232(2):420-30 [15286314.001]
  • [Cites] Radiologe. 2001 Jan;41(1):8-15 [11220102.001]
  • [Cites] Rofo. 2003 Jun;175(6):835-43 [12811698.001]
  • [Cites] Int J Colorectal Dis. 2003 Jan;18(1):63-72 [12458384.001]
  • [Cites] Rofo. 2000 Jan;172(1):61-7 [10719465.001]
  • [Cites] Acad Radiol. 2003 Jul;10 (7):739-50 [12862283.001]
  • [Cites] Radiographics. 2004 Jul-Aug;24(4):921-35 [15256618.001]
  • [Cites] Rofo. 2003 Jul;175(7):889-91 [12847642.001]
  • [Cites] Eur Radiol. 1999;9 Suppl 3:S382-7 [10602934.001]
  • [Cites] Radiology. 2004 Sep;232(3):799-809 [15284434.001]
  • [Cites] Eur Radiol. 2001;11 Suppl 3:E15-26 [11793049.001]
  • [Cites] Radiology. 2000 Apr;215(1):153-61 [10751481.001]
  • [Cites] Int J Colorectal Dis. 2001 Aug;16(4):247-56 [11515685.001]
  • [Cites] Radiol Med. 2004 Mar;107(3):155-65 [15031681.001]
  • [Cites] Radiology. 2003 Dec;229(3):798-805 [14563903.001]
  • [Cites] Rofo. 2000 Apr;172(4):361-6 [10961221.001]
  • [Cites] Z Gastroenterol. 2001 Apr;39(4):287-9, 292-4 [11367977.001]
  • [Cites] Radiology. 2000 Aug;216(2):411-7 [10924562.001]
  • [Cites] Rofo. 2004 Nov;176(11):1607-16 [15497079.001]
  • (PMID = 15912320.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


76. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy].
  • The cholecystectomy results in change of cholic acids flow into intestine.
  • Permanent type of the bile flow provokes the increase of proliferation of colic epithelial cells and increases the risk for development of right-sided colorectal tumors.
  • Meanwhile morphological features of colorectal tumors at the patients with cholecystectomy are still remaining to be clarified.
  • The goal of the study was to investigate immunohistochemical markers of proliferation and apoptosis in colorectal adenomas and adenocarcinomas at the patients with cholecystectomy.
  • 83 tumors and 49 samples of mucosa were immunostained with monoclonal mouse anti-human p53 protein (Dako) and monoclonal mouse anti-human Ki-67 antigen (Novocastra).
  • Thus, in benign colorectal tumors at the patients with retained function of gallbladder intensifying of epithelial cells proliferation is not accompanied with intensifying of apoptosis, and in malignant tumors a complete supression of apoptosis is observed.
  • The retaining of apoptosis in colorectal tumors compensates intensive proliferative activity with expectation of better prognosis.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / biosynthesis. Cell Proliferation. Cholecystectomy. Colon / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Intestinal Mucosa / metabolism. Ki-67 Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


77. Robles R, Marín C, Fernández JA, Ramírez P, Sánchez-Bueno F, Morales D, Luján JA, Abellán B, Ramírez M, Cascales P, Pérez D, Parrilla P: [Toward zero mortality in liver resection. Presentation of 200 consecutive cases]. Cir Esp; 2005 Jul;78(1):19-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common indication was liver metastases in 123 patients (61.5%), primary malignant liver tumors in 27 patients (13.5%), bile duct tumors in 27 patients (13.5%) and benign disease in 23 patients (11.5%).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Carcinoma. Liver Neoplasms
  • [MeSH-minor] Colorectal Neoplasms / mortality. Colorectal Neoplasms / secondary. Colorectal Neoplasms / surgery. Female. Humans. Male. Middle Aged. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cir Esp. 2005 Dec;78(6):392 [16420871.001]
  • [CommentIn] Cir Esp. 2005 Jul;78(1):1-2 [16420783.001]
  • (PMID = 16420786.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Spain
  •  go-up   go-down


78. Halazun KJ, Al-Mukhtar A, Aldouri A, Malik HZ, Attia MS, Prasad KR, Toogood GJ, Lodge JP: Right hepatic trisectionectomy for hepatobiliary diseases: results and an appraisal of its current role. Ann Surg; 2007 Dec;246(6):1065-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 275 patients, 160 had colorectal metastases, 49 had biliary tract cancers, 20 had hepatocellular carcinomas, 20 had other metastatic tumors, and 12 had benign diseases.
  • Concomitant procedures were carried out in 192 patients: caudate lobectomy in 45 patients, resection of tumors from the liver remnant in 57 patients, resection of the extrahepatic biliary tree in 45 patients, and lymphadenectomy in 45 patients.
  • Survivals for individual tumor types were acceptable, with 5-year survivals for colorectal metastasis and cholangiocarcinoma being 38% and 32%, respectively.
  • The outcome is not influenced by additional concomitant resection of tumors from the planned liver remnant.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2008 Jul;248(1):138-9; author reply 139-40 [18580219.001]
  • (PMID = 18043112.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Buchner AM, Shahid MW, Heckman MG, Krishna M, Ghabril M, Hasan M, Crook JE, Gomez V, Raimondo M, Woodward T, Wolfsen HC, Wallace MB: Comparison of probe-based confocal laser endomicroscopy with virtual chromoendoscopy for classification of colon polyps. Gastroenterology; 2010 Mar;138(3):834-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Virtual chromoendoscopy systems, such as Fujinon intelligent color enhancement and narrow band imaging, also have potential to differentiate neoplastic colorectal lesions.
  • Our primary aim was to compare sensitivity and specificity of pCLE to virtual chromoendoscopy for classification of colorectal polyps using histopathology as a gold standard.
  • Each polyp was diagnosed as benign or neoplastic based on confocal features according to modified Mainz criteria.
  • CONCLUSIONS: Confocal endomicroscopy demonstrated higher sensitivity with similar specificity in classification of colorectal polyps.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Colon / pathology. Colonic Neoplasms / diagnosis. Colonic Polyps / diagnosis. Colonoscopes. Colonoscopy / methods. Microscopy, Confocal / instrumentation. Molecular Imaging / instrumentation. Precancerous Conditions / diagnosis

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • (PMID = 19909747.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00874263
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Hague A, Hicks DJ, Hasan F, Smartt H, Cohen GM, Paraskeva C, MacFarlane M: Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br J Cancer; 2005 Feb 28;92(4):736-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis.
  • The death ligand TRAIL (Apo2L) has potential for cancer therapy, since tumour cells are thought to be more sensitive than normal cells.
  • We investigated whether sensitivity to TRAIL increases during the adenoma to carcinoma transition of colorectal carcinogenesis.
  • This finding was recapitulated in an in vitro model of tumour progression in which conversion of the adenoma cell line AA/C1 to a tumorigenic phenotype was associated with increased TRAIL sensitivity (P<0.001).
  • Increased TRAIL sensitivity during colorectal carcinogenesis has been previously attributed to changes in the balance between TRAIL receptors TRAIL-R1 and -R2 and "decoy" receptors TRAIL-R3 and -R4 during malignant progression.
  • In summary, during colorectal carcinogenesis, there is a marked increase in sensitivity to TRAIL-induced apoptosis associated with progression from benign to malignant tumour that could be exploited for colon cancer therapy, but alterations in cell surface TRAIL receptor expression may not be the primary reason for this change.
  • [MeSH-major] Adenoma / pathology. Apoptosis. Carcinoma / pathology. Cell Transformation, Neoplastic. Colorectal Neoplasms / pathology. Membrane Glycoproteins / metabolism. Receptors, Tumor Necrosis Factor / metabolism. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents / metabolism. Apoptosis Regulatory Proteins. Blotting, Western. Cell Line, Tumor. Electrophoresis, Polyacrylamide Gel. Flow Cytometry. GPI-Linked Proteins. Humans. Mice. Mice, Nude. Receptors, TNF-Related Apoptosis-Inducing Ligand. TNF-Related Apoptosis-Inducing Ligand. Tumor Necrosis Factor Decoy Receptors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 Mar 27;22(12):1807-16 [12660816.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3734-40 [12473583.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8628-33 [14634624.001]
  • [Cites] Histopathology. 2004 Mar;44(3):240-6 [14987227.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):594-604 [15196850.001]
  • [Cites] J Biol Chem. 2004 Aug 20;279(34):35829-39 [15155747.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6666-72 [15374982.001]
  • [Cites] Cell Death Differ. 2004 Oct;11(10):1084-91 [15243584.001]
  • [Cites] Cancer Res. 1976 Dec;36(12):4562-9 [1000501.001]
  • [Cites] Int J Cancer. 1984 Jul 15;34(1):49-56 [6746117.001]
  • [Cites] Cancer Res. 1989 Mar 1;49(5):1282-6 [2917357.001]
  • [Cites] Cancer Res. 1990 Aug 1;50(15):4724-30 [2369746.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):785-90 [1428233.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):498-505 [8397167.001]
  • [Cites] Nature. 1994 Sep 22;371(6495):346-7 [8090205.001]
  • [Cites] J Cell Sci. 1994 Dec;107 ( Pt 12):3569-77 [7706406.001]
  • [Cites] Immunity. 1995 Dec;3(6):673-82 [8777713.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):12687-90 [8663110.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72(5):898-905 [9311611.001]
  • [Cites] J Biol Chem. 1997 Oct 10;272(41):25417-20 [9325248.001]
  • [Cites] Immunity. 1997 Dec;7(6):813-20 [9430226.001]
  • [Cites] Immunity. 1997 Dec;7(6):821-30 [9430227.001]
  • [Cites] Immunity. 1997 Dec;7(6):831-6 [9430228.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] J Immunol. 1998 Sep 15;161(6):2833-40 [9743343.001]
  • [Cites] J Biol Chem. 1998 Dec 4;273(49):33091-8 [9830064.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):629-30 [9872307.001]
  • [Cites] Nat Med. 1999 Feb;5(2):146-7 [9930856.001]
  • [Cites] Cancer Lett. 1998 Nov 27;133(2):197-204 [10072170.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2597-605 [10072501.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4153-9 [10435597.001]
  • [Cites] Oncogene. 2001 Mar 22;20(12):1476-85 [11313891.001]
  • [Cites] FEBS Lett. 2002 Jan 2;510(1-2):37-40 [11755527.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):659-66 [11874999.001]
  • [Cites] Int J Oncol. 2002 Sep;21(3):643-8 [12168112.001]
  • [Cites] Oncogene. 2002 Oct 3;21(44):6809-18 [12360407.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6153-8 [10626806.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):335-46 [10690508.001]
  • [Cites] J Cell Biol. 2000 Mar 20;148(6):1239-54 [10725337.001]
  • [Cites] J Immunol. 2000 Apr 15;164(8):3961-70 [10754286.001]
  • [Cites] Biochem J. 2000 May 15;348 Pt 1:93-101 [10794718.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1645-51 [11245478.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):409-16 [11283615.001]
  • [Cites] J Pathol. 2003 Jul;200(3):327-35 [12845629.001]
  • (PMID = 15685228.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10A protein, human; 0 / TNFRSF10B protein, human; 0 / TNFRSF10C protein, human; 0 / TNFSF10 protein, human; 0 / Tnfrsf10b protein, mouse; 0 / Tnfsf10 protein, mouse; 0 / Tumor Necrosis Factor Decoy Receptors; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC2361885
  •  go-up   go-down


81. Boni L, Dionigi G, Cassinotti E, Di Giuseppe M, Diurni M, Rausei S, Cantore F, Dionigi R: Single incision laparoscopic right colectomy. Surg Endosc; 2010 Dec;24(12):3233-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laparoscopic surgery has been fully validated as alternative, minimally invasive treatment for different benign and malignant conditions.
  • METHODS: After signed, informed consent was obtained, patients with malignant tumors or large polyps of the right colon underwent single-incision colonic resection through a 3-cm incision using two different single-port devices and articulated or coaxial curved instruments.
  • The mean postoperative stay was 5 ± 1.2 days (range, 4-14), and mean lymph node retrieval and tumor-free margins was 24 ± 7 (range, 29-15) and 8 ± 3 (range, 6-12) cm, respectively.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / surgery. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2007 Mar;204(3):439-46 [17324779.001]
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1013-6 [18607608.001]
  • [Cites] Colorectal Dis. 2011 Apr;13(4):393-8 [20002691.001]
  • [Cites] Cancer Treat Rev. 2008 Oct;34(6):498-504 [18468803.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Gastrointest Endosc. 2008 Oct;68(4):760-6 [18926184.001]
  • [Cites] Colorectal Dis. 2008 Oct;10(8):823-6 [18684153.001]
  • [Cites] Surg Endosc. 2009 Jul;23(7):1419-27 [19347400.001]
  • [Cites] Surg Endosc. 2010 Apr;24(4):888-90 [19760335.001]
  • [Cites] Dis Colon Rectum. 2009 Apr;52(4):725 [19404081.001]
  • [Cites] Surg Endosc. 2007 Sep;21(9):1503-7 [17641928.001]
  • [Cites] Surg Technol Int. 2009 Apr;18:19-25 [19579186.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):111-7 [17185089.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):908-12 [19474690.001]
  • [Cites] Dis Colon Rectum. 2009 May;52(5):1021-4 [19502875.001]
  • [Cites] Surgeon. 2008 Dec;6(6):357-60 [19110824.001]
  • [Cites] Arch Surg. 2009 Aug;144(8):734-8 [19687377.001]
  • (PMID = 20464415.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


82. Øgreid D, Hamre E: Stool DNA analysis detects premorphological colorectal neoplasia: a case report. Eur J Gastroenterol Hepatol; 2007 Aug;19(8):725-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stool DNA analysis detects premorphological colorectal neoplasia: a case report.
  • Colorectal cancers usually develop from benign adenomas in a lengthy period of 5-10 years.
  • Our patient did not present any signs or symptoms of colorectal disease during his two visits to the endoscopist.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. DNA, Neoplasm / analysis. Feces / chemistry. Precancerous Conditions / diagnosis
  • [MeSH-minor] Colonic Polyps / diagnosis. Genetic Markers. Humans. Male. Middle Aged. Mutation. Neoplastic Syndromes, Hereditary / diagnosis. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625445.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


83. Ma TL, Ni PH, Zhong J, Tan JH, Qiao MM, Jiang SH: Low expression of XIAP-associated factor 1 in human colorectal cancers. Chin J Dig Dis; 2005;6(1):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low expression of XIAP-associated factor 1 in human colorectal cancers.
  • The aims of the present study were: (i) to investigate the expression of XAF1 in human colorectal cancers (CRC) both in vitro and in vivo, and (ii) to evaluate the possibility of XAF1 as a new tumor marker.
  • The expression of XAF1 in tissue was relatively lower in primary CRC compared with a relatively higher level in benign colorectal tumors (P < 0.01).
  • Although the XAF1 expression in circulation of those with CRC was also lower than in those with benign tumors, there was no statistical significance (P > 0.05).
  • CONCLUSIONS: The present results suggest that the low expression of XAF1 in tumor tissue coincides with a similar level in the peripheral circulation, which contributes at least part to the malignant behavior of CRC.
  • Integrating the XAF1 relative expression value with the other three traditional tumor biomarkers created a four-parameter assay that significantly improved the rate of diagnosis of CRC.
  • [MeSH-major] Biomarkers, Tumor / blood. Colonic Neoplasms / genetics. Colonic Neoplasms / physiopathology. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Aged. Apoptosis. Case-Control Studies. Female. Gene Expression Profiling. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Zinc Fingers

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667552.001).
  • [ISSN] 1443-9611
  • [Journal-full-title] Chinese journal of digestive diseases
  • [ISO-abbreviation] Chin J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / XAF1 protein, human
  •  go-up   go-down


84. Roessler M, Rollinger W, Mantovani-Endl L, Hagmann ML, Palme S, Berndt P, Engel AM, Pfeffer M, Karl J, Bodenmüller H, Rüschoff J, Henkel T, Rohr G, Rossol S, Rösch W, Langen H, Zolg W, Tacke M: Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol Cell Proteomics; 2006 Nov;5(11):2092-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis.
  • The purpose of this study was to identify and validate novel serological protein biomarkers of human colorectal cancer (CRC).
  • M., Schneidinger, B., Pfeffer, M., Andres, H., Karl, J., Bodenmuller, H., Ruschoff, J., Henkel, T., Rohr, G., Rossol, S., Rosch, W., Langen, H., Zolg, W., and Tacke, M. (2005) Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin.
  • The PSME3-containing spot on tumor gels showed no visible difference to the corresponding spot on matched control gels.
  • MS analysis revealed the presence of two proteins, PSME3 and annexin 4 (ANXA4) in one and the same spot on tumor gels, whereas the matched spot contained only one protein, ANXA4, on control gels.
  • Finally by developing a highly sensitive immunoassay, PSME3 could be detected in human sera and was significantly elevated in CRC patients compared with healthy donors and patients with benign bowel disease.
  • We propose that PSME3 be considered a novel serum tumor marker for CRC that may have significance in the detection and in the management of patients with this disease.
  • [MeSH-major] Autoantigens / blood. Biomarkers, Tumor / blood. Colorectal Neoplasms / diagnosis. Electrophoresis, Gel, Two-Dimensional. Mass Spectrometry / methods. Proteasome Endopeptidase Complex / blood


85. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ, Hoon DS: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol; 2005 Apr 20;23(12):2744-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.
  • PURPOSE: Liver metastasis is the predominant cause of colorectal cancer (CRC) related mortality.
  • METHODS: CRC cell lines (n = 6) and tumor specimens (n = 139) from patients with different American Joint Committee on Cancer (AJCC) stages of CRC were assessed.
  • CXCR4 expression in tumor and benign specimens was assessed by quantitative real-time reverse transcription polymerase chain reaction and correlated with disease recurrence and overall survival.
  • RESULTS: High CXCR4 expression in tumor specimens (n = 57) from AJCC stage I/II patients was associated with increased risk for local recurrence and/or distant metastasis (risk ratio, 1.35; 95% CI, 1.09 to 1.68; P = .0065).
  • High CXCR4 expression in primary tumor specimens (n = 35) from AJCC stage IV patients correlated with worse overall median survival (9 months v 23 months; RR, 2.53; 95% CI, 1.19 to 5.40; P = .016).
  • CXCR4 expression was significantly higher in liver metastases (n = 39) compared with primary CRC tumors (n = 100; P < .0001).
  • [MeSH-major] Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Gene Expression Profiling. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Neoplasm Recurrence, Local / genetics. Receptors, CXCR4 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / physiopathology. Prognosis. Risk Factors. Signal Transduction. Survival Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837989.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA90848-02
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, CXCR4
  •  go-up   go-down


86. Ohta M, Seto M, Ijichi H, Miyabayashi K, Kudo Y, Mohri D, Asaoka Y, Tada M, Tanaka Y, Ikenoue T, Kanai F, Kawabe T, Omata M: Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology; 2009 Jan;136(1):206-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression.
  • BACKGROUND & AIMS: Although colorectal cancer (CRC) progression has been associated with alterations in KRAS and RAS signaling, not all CRC cells have KRAS gene mutations.
  • The expression of the RAS protein activator like-1 (RASAL1) was examined in clinical colorectal neoplasms using immunohistochemistry.
  • The clinicopathologic (age, sex, and tumor site and grade) and molecular (KRAS gene mutation, as well as CTNNB1 and TP53 expression patterns) factors that could affect RASAL1 expression were examined.
  • RASAL1 expression was detected in 46.9% (30/64) of adenocarcinoma, 17.4% (8/46) of large adenoma, and no (0/42) small adenoma samples.
  • RASAL1 expression levels were correlated with the presence of wild-type KRAS gene in CRC tumor samples (P= .0010), distal location (P= .0066), and abnormal expression of TP53 (P= .0208).
  • Reductions in RASAL1 expression were detected more frequently in advanced lesions than in small adenomas, suggesting that RASAL1 functions in the progression of benign colonic neoplasms.
  • [MeSH-major] Colorectal Neoplasms / etiology. Tumor Suppressor Proteins / physiology. ras GTPase-Activating Proteins / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. DNA Methylation. Disease Progression. Female. Gene Silencing. Genes, ras. Humans. Male. Middle Aged. Signal Transduction


87. Maksimović RM, Dunjić MS, Lilić GB, Milenković RM, Masulović DM, Milićević M: [Diagnostic value of diffusion weighted imaging in assessment of malignant focal liver lesions]. Acta Chir Iugosl; 2009;56(4):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The study included 63 patients with focal hepatic lesions: fourteen patients (22.2%) with hepatocellular carcinoma (HCC), 16 patients (25.4%) with hepatic metastatic colorectal tumors, 17 patients (26.9%) with cavernous haemangioma and 16 patients (25.4%) with hepatic cysts.
  • Furthermore, there was statistically significant difference between benign lesions (haemangiom and cysts, 2.36 +/- 0.43 x 10(-3) s/mm2), and malignant diseases (HCC and secondary tumors, 1.52 +/- 0.58 x 10(-3) s/mm2), t = 5,6, p < 0.01.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging. Liver Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Hepatocellular / diagnosis. Female. Hemangioma, Cavernous / diagnosis. Humans. Liver Diseases / diagnosis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20420007.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


88. Zheng JP, Shao GL, Chen YT, Fan SF, Yang JM: [Feasibility study on CT guided percutaneous incisional needle biopsy for deep pelvic masses by different puncture approaches]. Zhonghua Zhong Liu Za Zhi; 2009 Oct;31(10):786-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-four malignant lesions were confirmed by pathology, including 30 adenocarcinomas, 19 squamous cell carcinomas, 5 unclassified malignant tumors, 3 small cell carcinomas, 2 malignant giant cell tumors of bone, 2 hepatocellular carcinomas and 3 false negative lesions which were confirmed at the second PINBs as malignant tumors, respectively.
  • Benign neoplasms were confirmed in 8 cases, including fibrosis tissue in 6 lesions, bone tuberculosis in 1 and ovarian cyst in 1.
  • No hematoma, nerve damage, infection, and tumor transplantation in pelvic cavity developed after the PINB procedure.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / methods. Carcinoma, Squamous Cell / pathology. Pelvic Neoplasms / pathology. Pelvis / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / pathology. Colorectal Neoplasms / radiography. Diagnosis, Computer-Assisted / methods. Feasibility Studies. Female. Fibrosis / pathology. Fibrosis / radiography. Follow-Up Studies. Humans. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Male. Middle Aged. Tomography, X-Ray Computed. Uterine Neoplasms / pathology. Uterine Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021836.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


89. Shi H, Li Y, Wei L, Sun L: Primary colorectal inflammatory myofibroblastic tumour: a clinicopathological and immunohistochemical study of seven cases. Pathology; 2010 Apr;42(3):235-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary colorectal inflammatory myofibroblastic tumour: a clinicopathological and immunohistochemical study of seven cases.
  • AIMS: Primary colorectal inflammatory myofibroblastic tumours are rare.
  • METHODS: Clinical and pathological data of seven cases of colorectal inflammatory myofibroblastic tumour were reviewed.
  • The tumour size ranged from 3.8 cm to 6.3 cm in greatest dimension.
  • Five patients were alive without evidence of disease after tumour resection.
  • Two patients had a tumour recurrence 14 and 18 months after the initial surgery, respectively.
  • CONCLUSIONS: Colorectal inflammatory myofibroblastic tumours are rare, benign or low malignant tumours and ALK positivity is helpful in pathological diagnosis.
  • [MeSH-major] Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Neoplasms, Muscle Tissue / metabolism. Neoplasms, Muscle Tissue / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350216.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


90. Königsrainer I, Steurer W, Witte M, Königsrainer A: Liver resection without hilus preparation and with selective intrahepatic hilus stapling for benign tumors and liver metastasis. Langenbecks Arch Surg; 2007 Jul;392(4):485-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection without hilus preparation and with selective intrahepatic hilus stapling for benign tumors and liver metastasis.
  • Extrahepatic isolation of portal vein, hepatic artery and hepatic duct, as well as lymphadenectomy of the liver hilum are generally accepted steps of liver resection, even for metastatic and benign indications.
  • MATERIALS AND METHODS: Thirty-eight consecutive patients with resection for metastases and benign liver tumors were selected.
  • To date, no tumor recurrence was found in the hilum during the follow-up period.
  • Hilar dissection can, thus, be avoided in liver metastasis and benign liver tumors.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery. Surgical Stapling
  • [MeSH-minor] Aged. Colorectal Neoplasms / pathology. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1285-90; discussion 1290-1 [10528765.001]
  • [Cites] J Surg Oncol. 2005 Apr 1;90(1):43-5 [15786414.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):137-8; author reply 138 [16371749.001]
  • [Cites] Ann Surg. 2005 Apr;241(4):582-90 [15798459.001]
  • [Cites] Br J Surg. 2006 Jun;93(6):685-9 [16703653.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):286-91 [9880776.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):202-9 [14745328.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):260-4 [16858189.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):111-9 [12832973.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):397-406; discussion 406-7 [12368667.001]
  • [Cites] World J Surg. 1995 Sep-Oct;19(5):764-7 [7571678.001]
  • [Cites] Ann Surg. 2001 Jan;233(1):45-50 [11141224.001]
  • [Cites] Ann Surg. 1996 Aug;224(2):155-61 [8757378.001]
  • [Cites] Ann Surg. 1997 Dec;226(6):704-11; discussion 711-3 [9409569.001]
  • [Cites] World J Gastroenterol. 2006 Feb 14;12(6):935-9 [16521223.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):942-5 [8813780.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):121-4 [8653335.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):210-5 [10024102.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):814-22, discussion 822-3 [16327491.001]
  • (PMID = 17530278.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


91. Nio Y, Iguchi C, Itakura M, Toga T, Hashimoto K, Koike M, Omori H, Sato Y, Endo S: High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor-like disorders. Anticancer Res; 2009 May;29(5):1607-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor-like disorders.
  • In the patients with benign and malignant thyroid tumor or tumor-like disorders, the incidence of other malignancies was surveyed, and the frequency of thyroid cancer in patients with breast cancer was also surveyed.
  • PATIENTS AND METHODS: Between 1982 and 2005, a total of 201 female patients received surgery for tumor or tumor-like disorders, including 65 carcinoma, 68 adenoma, 61 adenomatous goiter and 7 chronic thyroiditis cases.
  • RESULTS: The overall incidence rate of breast cancer was 16.4% (33/201) in the patients, who received thyroid surgeries and was much higher than other malignancies: 2.0% gastric cancer, 1.0% uterine and colorectal cancer.
  • [MeSH-major] Breast Neoplasms / epidemiology. Neoplasms, Second Primary / complications. Thyroid Neoplasms / complications


92. Mithieux F, Coriat R, De La Fouchardière C, Méeus P, Rivoire M: [Pseudo-Meigs syndrome: particular management of ovarian metastases in colorectal cancer]. Gastroenterol Clin Biol; 2008 Mar;32(3):261-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudo-Meigs syndrome: particular management of ovarian metastases in colorectal cancer].
  • [Transliterated title] Le pseudosyndrome de Meigs, particularité dans la prise en charge des métastases ovariennes de cancer colorectal.
  • Ascites and/or pleural effusion with ovarian metastases in colorectal cancer are usually related to peritoneal carcinomatosis.
  • Pseudo-Meigs syndrome is a characterized by non-malignant ascites and/or pleural effusion caused by pelvic tumors other than solid benign ovarian tumors.
  • We treated two patients who developed this syndrome in a context of colorectal cancer.
  • In the presence of acellular ascites with ovarian metastases from colorectal cancer, diagnosis of pseudo-Meigs syndrome may allow surgical treatment with curative intent.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Meigs Syndrome / therapy. Ovarian Neoplasms / secondary


93. Franklin ME Jr, Leyva-Alvizo A, Abrego-Medina D, Glass JL, Treviño J, Arellano PP, Portillo G: Laparoscopically monitored colonoscopic polypectomy: an established form of endoluminal therapy for colorectal polyps. Surg Endosc; 2007 Sep;21(9):1650-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopically monitored colonoscopic polypectomy: an established form of endoluminal therapy for colorectal polyps.
  • BACKGROUND: Benign polyps, the most common disorders of the colon, are considered by many to be premalignant lesions.
  • [MeSH-minor] Aged. Colonic Neoplasms / diagnosis. Colonic Polyps / diagnosis. Colonic Polyps / surgery. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterol Hepatol. 2000 May;23(5):224-7 [10902274.001]
  • [Cites] Gastroenterol Clin Biol. 1998 Apr;22(4):425-30 [9762273.001]
  • [Cites] Surg Technol Int. 2003;11:97-101 [12931289.001]
  • [Cites] Surg Laparosc Endosc. 1995 Apr;5(2):137-8 [7773461.001]
  • [Cites] Rozhl Chir. 1999 Jan;78(1):3-5 [10377760.001]
  • [Cites] Gastrointest Endosc. 1968 Aug;15(1):27 [5675566.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1246-9 [11005491.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Aug;16(4):867-74 [12418052.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):746-8 [11357040.001]
  • [Cites] Zentralbl Chir. 2003 Mar;128(3):195-8 [12695924.001]
  • [Cites] Minerva Chir. 2003 Dec;58(6):791-5 [14663406.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):231-2 [10064752.001]
  • [Cites] Surg Endosc. 1996 Jun;10(6):666-7 [8662410.001]
  • [Cites] Ann Chir. 1997;51(9):986-9 [10868040.001]
  • [Cites] Semin Surg Oncol. 1998 Oct-Nov;15(3):183-8 [9779630.001]
  • (PMID = 17318689.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Shaikh S, Nabi G, O'Kelly T, Swami SK: Endoscopic trans-anal resection of rectal tumours: critical appraisal of an interdisciplinary approach. Colorectal Dis; 2007 Mar;9(3):235-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Endoscopic trans-anal resection (ETAR) is an accepted technique for treating benign rectal adenomas that relies on technical expertise with the urological resectoscope.
  • We present our experience with ETAR in an interdisciplinary setting combining the decision-making of the colorectal surgeon with the technical skill of the urologist.
  • METHOD: Assessment of all patients with adenomas and their subsequent care was organized by the colorectal team.
  • Mean tumour distance from the anal verge was 7 cm (range 2-12 cm); the mean tumour area was 8 cm(2) (range 3-20 cm(2)); the mean operating time was 34 min (range 15-60 min) and the mean hospital stay was 32 h (range 24-120 h).
  • CONCLUSION: An interdisciplinary approach to ETAR uses available clinical resources efficiently as the colorectal surgeon does need to acquire the technical skills of endoscopic resection.
  • Our results compare favourably with other published series and this approach can be adopted by any centre where colorectal and urological surgeons work together.
  • [MeSH-major] General Surgery. Interdisciplinary Communication. Proctoscopy / methods. Rectal Neoplasms / surgery. Urology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17298621.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


95. Bonin EA, Baron TH: Update on the indications and use of colonic stents. Curr Gastroenterol Rep; 2010 Oct;12(5):374-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Self-expandable metal stent (SEMS) placement is a minimally invasive option for achieving acute colonic decompression in obstructed colorectal cancer.
  • Colorectal stenting offers nonoperative, immediate, and effective colon decompression and allows bowel preparation for an elective oncologic resection.
  • Despite concerns of tumor seeding following endoscopic colorectal stent placement, no difference exists in oncologic long-term survival between patients who undergo stent placement followed by elective resection and those undergoing emergency bowel resection.
  • Colorectal stents have also been used in selected patients with benign colonic strictures.
  • Patients with benign colonic stricture with acute colonic obstruction who are at high risk for emergency surgery can gain temporary relief of obstruction after SEMS placement; the stent can be removed en bloc with the colon specimen at surgery.
  • This article reviews the techniques and indications of SEMS placement for benign and malignant colorectal obstructions.
  • [MeSH-major] Colonoscopy / methods. Colorectal Neoplasms / surgery. Intestinal Obstruction / surgery. Stents / adverse effects
  • [MeSH-minor] Acute Disease. Colon / pathology. Colon / surgery. Colonic Diseases / etiology. Colonic Diseases / surgery. Constriction, Pathologic / surgery. Humans. Palliative Care. Pelvic Neoplasms / complications. Pelvic Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2009 Oct;19(5):e202-5 [19851253.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Colorectal Dis. 2009 Feb;11(2):178-83 [18477021.001]
  • [Cites] Lancet. 2006 Nov 4;368(9547):1573-4 [17084754.001]
  • [Cites] Scand J Surg. 2009;98(3):143-7 [19919918.001]
  • [Cites] J Gastrointest Surg. 2009 May;13(5):960-5 [19159986.001]
  • [Cites] South Med J. 2009 Dec;102(12):1257-9 [20016435.001]
  • [Cites] World J Surg. 2009 Jun;33(6):1281-6 [19363580.001]
  • [Cites] Gastrointest Endosc. 2008 Jan;67(1):68-73 [18028916.001]
  • [Cites] J Am Coll Surg. 2001 Jun;192(6):719-25 [11400965.001]
  • [Cites] Brachytherapy. 2009 Jul-Sep;8(3):313-7 [19211311.001]
  • [Cites] Can J Gastroenterol. 2006 Dec;20(12):779-85 [17171197.001]
  • [Cites] Arch Surg. 2009 Dec;144(12):1127-32 [20026830.001]
  • [Cites] Surg Endosc. 2007 Feb;21(2):225-33 [17160651.001]
  • [Cites] Gastrointest Endosc. 2010 Apr;71(4):799-805 [20363422.001]
  • [Cites] Gastrointest Endosc. 2010 Mar;71(3):560-72 [20189515.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] AJR Am J Roentgenol. 2009 Jul;193(1):248-54 [19542421.001]
  • [Cites] Dis Colon Rectum. 2003 Jan;46(1):24-30 [12544518.001]
  • [Cites] World J Gastroenterol. 2007 Aug 7;13(29):3977-80 [17663513.001]
  • [Cites] Curr Oncol Rep. 2009 Jul;11(4):293-7 [19508834.001]
  • [Cites] Curr Opin Gastroenterol. 2009 Jan;25(1):50-4 [19119510.001]
  • [Cites] Scand J Gastroenterol. 2010 Jun;45(6):725-31 [20205505.001]
  • [Cites] Colorectal Dis. 2009 May;11(4):405-9 [18513190.001]
  • [Cites] Radiology. 2010 Mar;254(3):774-82 [20177092.001]
  • [Cites] Dis Colon Rectum. 2009 Sep;52(9):1657-61 [19690497.001]
  • [Cites] Dis Colon Rectum. 2009 Jul;52(7):1272-7 [19571704.001]
  • [Cites] J Am Coll Surg. 2010 Jan;210(1):45-53 [20123331.001]
  • [Cites] BMC Surg. 2007 Jul 03;7:12 [17608947.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Am Surg. 2009 Oct;75(10):897-900 [19886130.001]
  • [Cites] Expert Rev Gastroenterol Hepatol. 2008 Jun;2(3):399-409 [19072388.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 May;21(5):585-6 [19282771.001]
  • [Cites] Dig Dis Sci. 2010 Jun;55(6):1732-7 [19693667.001]
  • [Cites] Surg Endosc. 2010 Mar;24(3):525-30 [19597776.001]
  • [Cites] Colorectal Dis. 2011 May;13(5):549-54 [20082633.001]
  • [Cites] Dis Colon Rectum. 2010 Feb;53(2):200-12 [20087096.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2007 Apr;17(2):323-39, vi [17556151.001]
  • [Cites] Gastrointest Endosc. 2009 Jun;69(7):1282-7 [19286179.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):2051-7 [15447772.001]
  • [Cites] Gastrointest Endosc. 2009 Mar;69(3 Pt 2):675-80 [19251009.001]
  • [Cites] Surgery. 2008 Nov;144(5):786-92 [19081022.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Nov;7(11):1174-6 [19631290.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):1-7 [15672048.001]
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1007-12 [18594837.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):921-4 [17140899.001]
  • [Cites] Am J Gastroenterol. 2010 May;105(5):1087-93 [19935785.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):454-62 [17704890.001]
  • (PMID = 20703837.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


96. Hong R, Lim SC: Granular cell tumor of the cecum with extensive hyalinization and calcification: a case report. World J Gastroenterol; 2009 Jul 14;15(26):3315-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the cecum with extensive hyalinization and calcification: a case report.
  • A granular cell tumor (GCT) is a benign neoplasm of unclear histogenesis that is generally believed to be of nerve sheath origin.
  • In addition to the tumor, endoscopic examination revealed the presence of a 5-mm-polyp in the descending colon and multiple tiny polyps in the sigmoid colon and rectum.
  • Histological examination demonstrated a cecal tumor 1.5 cm x 1.0 cm x 0.7 cm with a hard consistency; in cut sections, mixed cells with yellowish and whitish portions were seen.
  • The tumor was located between the mucosa and subserosa, and was composed of plump histiocyte-like tumor cells with abundant granular eosinophilic cytoplasm, which were immunoreactive for S-100 protein, vimentin, neuron-specific enolase, inhibin-alpha and calretinin.
  • The tumor showed extensive hyalinization and focal dystrophic calcification.
  • Extensive hyalinization and calcification showing involution of tumor cells suggest benign clinical behavior of GCT.
  • [MeSH-major] Calcinosis / pathology. Cecum / pathology. Granular Cell Tumor / pathology. Hyalin / metabolism
  • [MeSH-minor] Biomarkers, Tumor. Calbindin 2. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Humans. Male. Middle Aged. Phosphopyruvate Hydratase. S100 Calcium Binding Protein G. S100 Proteins. Vimentin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ugeskr Laeger. 2006 May 22;168(21):2080-1 [16768929.001]
  • [Cites] J Oral Pathol Med. 1997 Apr;26(4):164-9 [9176790.001]
  • [Cites] J Craniofac Surg. 2008 Nov;19(6):1691-4 [19098584.001]
  • [Cites] J Oral Pathol Med. 2009 Jan;38(1):150-9 [19192059.001]
  • [Cites] J Gastroenterol. 2000;35(8):631-4 [10955603.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1200-3 [11688581.001]
  • [Cites] J Gastroenterol. 2003;38(4):385-9 [12743780.001]
  • [Cites] World J Gastroenterol. 2004 Aug 15;10(16):2452-4 [15285042.001]
  • [Cites] Mt Sinai J Med. 1979 Mar-Apr;46(2):195-8 [220528.001]
  • [Cites] J Surg Oncol. 1980;13(4):301-16 [6246310.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Apr;65(4):427-35 [2834681.001]
  • [Cites] Am J Gastroenterol. 1989 Jun;84(6):656-9 [2543214.001]
  • [Cites] Am J Gastroenterol. 1993 Feb;88(2):311-5 [8424442.001]
  • [Cites] Am J Gastroenterol. 1993 Oct;88(10):1785-7 [8213726.001]
  • [Cites] Pathologica. 1995 Apr;87(2):175-8 [8532413.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Dec;80(6):687-97 [8680977.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1997 Jan;94(1):27-32 [9028140.001]
  • [Cites] Turk J Gastroenterol. 2008 Mar;19(1):73-4 [18386247.001]
  • (PMID = 19598311.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / S100 Proteins; 0 / Vimentin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Other-IDs] NLM/ PMC2710791
  •  go-up   go-down


97. Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, Ferrara N: Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci U S A; 2007 Jun 19;104(25):10625-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-VEGF-A monoclonal antibodies, in combination with chemotherapy, result in a survival benefit in patients with metastatic colorectal and non-small cell lung cancer, but little is known regarding the impact of anti-VEGF-A therapy on benign or premalignant tumors.
  • To investigate whether tumor growth in Apc+/min mice is mediated by VEGF-A-dependent angiogenesis, we used two independent approaches to inhibit VEGF-A: monotherapy with a monoclonal antibody (Mab) targeting VEGF-A and genetic deletion of VEGF-A selectively in intestinal epithelial cells.
  • Short-term (3 or 6 weeks) treatment with anti-VEGF-A Mab G6-31 resulted in a nearly complete suppression of adenoma growth throughout the small intestine.
  • Deletion of VEGF-A in intestinal epithelial cells of Apc+/min mice yielded a significant inhibition of tumor growth, albeit of lesser magnitude than that resulting from Mab G6-31 administration.
  • These results establish that inhibition of VEGF-A signaling is sufficient for tumor growth cessation and confers a long-term survival benefit in an intestinal adenoma model.
  • [MeSH-minor] Adenoma / blood supply. Adenoma / genetics. Adenoma / immunology. Adenoma / therapy. Animals. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Gene Deletion. In Situ Hybridization. Intestinal Neoplasms / blood supply. Intestinal Neoplasms / genetics. Intestinal Neoplasms / immunology. Intestinal Neoplasms / therapy. Mice. Mice, Inbred C57BL. Signal Transduction / immunology. Survival Analysis. Time Factors

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5209-18 [10537299.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):316-25 [16507828.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5040-4 [11016626.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6253-8 [11103779.001]
  • [Cites] Cancer Lett. 2002 Jan 25;175(2):157-63 [11741743.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):506-11 [11809702.001]
  • [Cites] Dev Dyn. 2002 May;224(1):90-102 [11984877.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1351-9 [12151354.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33275-83 [12065599.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Dec;11(12):1715-36 [12457433.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):391-400 [12750232.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1445-52 [12778076.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Curr Biol. 2003 Sep 30;13(19):1721-7 [14521839.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] J Exp Med. 1972 Aug 1;136(2):261-76 [5043412.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Dec;82(24):8488-92 [3909146.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Development. 1992 Jul;115(3):717-28 [1425351.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1789-97 [7535799.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2556-60 [8653697.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4267-73 [9331087.001]
  • [Cites] Prostate. 1998 Apr 1;35(1):1-10 [9537593.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):51-8 [9934849.001]
  • [Cites] Development. 1999 Mar;126(6):1149-59 [10021335.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4389-400 [15899831.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):951-61 [16278208.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):549-60 [16336962.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1710-7 [16685275.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2133-9 [16782971.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3478-83 [17360669.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • (PMID = 17553957.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1888576
  •  go-up   go-down


98. Misawa T, Shiba H, Usuba T, Nojiri T, Kitajima K, Uwagawa T, Toyama Y, Ishida Y, Ishii Y, Yanagisawa A, Kobayashi S, Yanaga K: Systemic inflammatory response syndrome after hand-assisted laparoscopic distal pancreatectomy. Surg Endosc; 2007 Aug;21(8):1446-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although the clinical benefits of hand-assisted laparoscopic surgery have been shown in several procedures including colorectal resection, splenectomy and gastrectomy, efficacy and invasiveness in pancreatic surgery have not been well investigated.
  • METHODS: Subjects comprised 8 patients underwent HALS-DP (with splenectomy, n = 7; without splenectomy, n = 1) for benign or low malignant pancreatic lesions between March 2004 and December 2005.
  • Indications for HALS-DP consisted of mucinous cystadenoma (n = 4), endocrine tumors (n = 2), serous cystadenoma (n = 1) and pancreatic pseudocyst (n = 1).
  • Controls comprised 9 patients who underwent conventional open distal pancreatectomy (Open-DP) for benign or low malignant lesions of the pancreas in the same period.
  • CONCLUSION: HALS-DP is safer and less invasive than Open-DP for benign or low malignant pancreatic tumors.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Pancreatic Neoplasms / surgery

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2002 Feb;16(2):234-9 [11967670.001]
  • [Cites] Surg Endosc. 2003 Apr;17(4):636-40 [12574925.001]
  • [Cites] J Am Coll Surg. 2005 Feb;200(2):191-7 [15664093.001]
  • [Cites] Surg Endosc. 2004 Apr;18(4):577-81 [15026923.001]
  • [Cites] Arch Surg. 2000 Oct;135(10):1137-40 [11030868.001]
  • [Cites] Endoscopy. 1997 May;29(4):298-308 [9255536.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):154-64 [10398903.001]
  • [Cites] Surg Endosc. 2003 Dec;17(12):2028-31 [14598159.001]
  • [Cites] Transplantation. 2001 Jul 27;72(2):284-90 [11477354.001]
  • [Cites] Ann Surg. 1991 Jan;213(1):3-12 [1824674.001]
  • [Cites] Gastroenterol Clin North Am. 1999 Dec;28(4):987-1005, viii [10695013.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2002 Sep;93(6):681-5 [12385092.001]
  • [Cites] Surg Endosc. 2003 Feb;17(2):324-7 [12384763.001]
  • [Cites] Crit Care Med. 1992 Jun;20(6):864-74 [1597042.001]
  • [Cites] Am J Surg. 2005 Jun;189(6):734-7 [15910728.001]
  • [Cites] Surg Endosc. 2000 Oct;14(10):891-5 [11080398.001]
  • [Cites] Surgery. 2006 Jan;139(1):39-45 [16364716.001]
  • [Cites] Arch Surg. 1999 May;134(5):477-85; discussion 485-6 [10323419.001]
  • [Cites] JAMA. 1995 Jan 11;273(2):117-23 [7799491.001]
  • [Cites] Urology. 2004 Sep;64(3):422-5 [15351556.001]
  • [Cites] Surg Laparosc Endosc. 1995 Dec;5(6):463-7 [8611994.001]
  • [Cites] Arch Surg. 2002 Dec;137(12):1348-52 [12470097.001]
  • [Cites] Crit Care Med. 1997 Dec;25(12):1994-2000 [9403749.001]
  • (PMID = 17593462.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


99. David GG, Al-Sarira AA, Willmott S, Cade D, Corless DJ, Slavin JP: Use of Hartmann's procedure in England. Colorectal Dis; 2009 Mar;11(3):308-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Hartmann's procedure is widely used in the management of complicated diverticular disease and for colorectal cancer.
  • Most emergency Hartmann's were performed for benign disease (2067, 72.5%) whereas a majority of the elective Hartmann's were performed for cancer (756, 68.9%).
  • A majority of Hartmann's are performed as an emergency for benign diseases and most of them are not reversed.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / surgery. Colostomy / methods. Diverticulum, Colon / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Diverticulosis and Diverticulitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2010 Feb;12(2):153-4 [19486083.001]
  • (PMID = 18513199.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


100. Abouzied MM, Crawford ES, Nabi HA: 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol; 2005 Sep;33(3):145-55; quiz 162-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 18F-FDG PET is emerging as a useful tool in the staging and restaging of many malignant neoplasms, such as lymphoma, lung cancer, colorectal cancer, head and neck cancer, breast cancer, and melanoma.
  • To accurately interpret 18F-FDG findings one must be familiar with the normal physiologic distribution of the tracer, frequently encountered physiologic variants, and benign pathologic causes of 18F-FDG uptake that can be confused with a malignant neoplasm.
  • The objectives of this article are to (a) describe the mechanism of 18F-FDG uptake, (b) list the patient preparation and pertinent patient history before 18F-FDG imaging, (c) describe the whole-body physiologic distribution of 18F-FDG, (d) list and discuss normal physiologic variants, and (e) list and discuss benign pathologic causes of 18F-FDG uptake.
  • [MeSH-major] Artifacts. Diagnostic Errors / prevention & control. Fluorodeoxyglucose F18 / pharmacokinetics. Neoplasms / metabolism. Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145222.001).
  • [ISSN] 0091-4916
  • [Journal-full-title] Journal of nuclear medicine technology
  • [ISO-abbreviation] J Nucl Med Technol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 48
  •  go-up   go-down






Advertisement